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Summary 
SUMMARY 
Platelet activation induces cytoskeletal rearrangements involving a change from 
discoid to spheric shape, secretion, and eventually adhesion and spreading on 
immobilized ligands. Small GTPases of the Rho family, such as Rac1 and Cdc42, are 
known to be involved in these processes by facilitating the formation of lamellipodia 
and filopodia, respectively. This thesis focuses on the role Rac1 and Cdc42 for 
platelet function and formation from their precursor cells, the megakaryocytes (MKs), 
using conditional knock-out mice.  
In the first part of the work, the involvement of Rac1 in the activation of the enzyme 
phospholipase (PL) C2 in the signaling pathway of the major platelet collagen 
receptor glycoprotein (GP) VI was investigated. It was found that Rac1 is essential 
for PLC2 activation independently of tyrosine phosphorylation of the enzyme, 
resulting in a specific platelet activation defect downstream of GPVI, whereas 
signaling of other activating receptors remains unaffected. Since Rac1-deficient mice 
were protected from arterial thrombosis in two different in vivo models, the GTPase 
might serve as a potential target for the development of new drugs for the treatment 
and prophylaxis of cardio- and cerebrovascular diseases.  
The second part of the thesis deals with the first characterization of MK- and platelet-
specific Cdc42 knock-out mice. Cdc42-deficient mice displayed mild thrombo-
cytopenia and platelet production from mutant MKs was markedly reduced. 
Unexpectedly, Cdc42-deficient platelets showed increased granule content and 
release upon activation, leading to accelerated thrombus formation in vitro and in 
vivo. Furthermore, Cdc42 was not generally required for filopodia formation upon 
platelet activation. Thus, these results indicate that Cdc42, unlike Rac1, is involved in 
multiple signaling pathways essential for proper platelet formation and function. 
Finally, the outcome of combined deletion of Rac1 and Cdc42 was studied. In 
contrast to single deficiency of either GTPase, platelet production from double-
deficient MKs was virtually abrogated, resulting in dramatic macrothrombocytopenia 
in the animals. Formed platelets were largely non-functional leading to a severe 
hemostatic defect and defective thrombus formation in double-deficient mice in vivo. 
These results demonstrate for the first time a functional redundancy of Rac1 and 
Cdc42 in the hematopoietic system. 
 
 IV
Zusammenfassung 
ZUSAMMENFASSUNG 
Umstrukturierungen des Zytoskeletts spielen eine bedeutende Rolle bei der 
Aktivierung von Thrombozyten und sind in diesem Zusammenhang unerlässlich für 
Formänderung, Sekretion, sowie für Adhäsion und Ausbreitung auf immobilisierten 
Adhäsionsproteinen. Es wird vermutet, dass kleine GTPasen der Rho-Proteinfamilie, 
wie z.B. Rac1 und Cdc42, maßgeblich an diesen Prozessen beteiligt sind, indem sie 
die Bildung von Lamellipodien bzw. Filopodien bewirken. Die hier vorliegende 
Dissertation beschäftigt sich mit der Funktion von Rac1 und Cdc42 sowohl für die 
Aktivierung von Thrombozyten, als auch für deren Neubildung aus ihren 
Vorläuferzellen, den Megakaryozyten (MKs). Zu diesem Zweck wurden konditionale 
Knock-out-Mäuse generiert und in vitro und in vivo analysiert. 
Der erste Teil der Arbeit beinhaltete die Untersuchung der Rolle von Rac1 im 
Signalweg des wichtigsten Thrombozyten-Kollagen-Rezeptors, Glykoprotein (GP) VI, 
dessen Stimulation zur Aktivierung des Enzyms Phospholipase 2 (PLC2) führt. Es 
konnte gezeigt werden, dass Rac1 notwendig für PLC2-Aktivierung ist, und zwar 
unabhängig von der simultan stattfindenden Tyrosin-Phosphorylierung des Enzyms. 
Dies führte dazu, dass in Rac1-defizienten Thrombozyten spezifisch der GPVI-
Signalweg blockiert war, während die Aktivierung durch andere Rezeptoren 
unverändert funktionierte. Da Rac1-defiziente Mäuse vor arteriellem Gefäßverschluss 
(Thrombose) in zwei verschiedenen in vivo Modellen geschützt waren, könnte Rac1 
einen potenziellen Angriffspunkt für die Entwicklung neuer antithrombotisch 
wirksamer Medikamente darstellen. 
Im zweiten Teil der Dissertation wurden erstmals die Auswirkungen eines MK- und 
Thrombozyten-spezifischen Cdc42-Knock-outs charakterisiert. Cdc42-defiziente 
Mäuse zeigten eine leichte Thrombozytopenie und die Neubildung von 
Thrombozyten aus defizienten MKs war merklich beeinträchtigt. Entgegen aller 
Erwartungen waren sowohl Inhalt, als auch Freisetzung von Granula aus Cdc42-
defizienten Thrombozyten stark erhöht, was zu beschleunigter Thrombusbildung in 
vitro und Gefäßverschluss in vivo führte. Überdies war Cdc42 generell nicht 
essentiell für die Ausbildung von Filopodien nach Thrombozytenaktivierung. Diese 
Ergebnisse deuten darauf hin, dass Cdc42 an einer Vielzahl von Signalwegen 
beteiligt ist, welche für die korrekte Bildung und Funktion von Thrombozyten 
unabdingbar sind. 
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Der letzte Teil der Arbeit beschäftigte sich mit den Auswirkungen einer Doppel-
defizienz von Rac1 und Cdc42. Im Gegensatz zur jeweiligen Einfachdefizienz war die 
Bildung von Thrombozyten aus doppeldefizienten MKs fast komplett blockiert, was 
eine stark ausgeprägte Makrothrombozytopenie in den betroffenen Tieren zur Folge 
hatte. Die wenigen gebildeten Thrombozyten waren in ihrer Funktion stark 
beeinträchtigt. Dies führte zusammen mit den extrem niedrigen Thrombozytenzahlen 
dazu, dass in doppeldefizienten Mäusen sowohl Hämostase als auch 
Thrombusbildung defekt waren. Diese Resultate zeigen erstmals eine funktionelle 
Redundanz von Rac1 und Cdc42 im hämatopoetischen System. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
1  Introduction 
 
1 INTRODUCTION 
 
Platelets are small anuclear discoid-shaped cells which are produced by 
fragmentation of megakaryocytes in the bone marrow and subsequently released into 
the blood stream. They evolved relatively late and are only found in mammals. The 
number of platelets in the blood is astonishingly high, in the range of 250,000/µl in 
humans and 1,000,000/µl in mice. Human platelets circulate in the blood for up to 10 
days, whereas the life span of murine platelets is restricted to approximately 5 days. 
Aged platelets are constantly cleared by the reticulo-endothelial system in spleen and 
liver and most of the produced platelets encounter this fate. However, upon damage 
of the endothelial cell layer in blood vessels, exposed components of the extracellular 
matrix (ECM) trigger rapid platelet adhesion and activation. Activated platelets 
release substances which lead, together with locally produced thrombin, to 
recruitment and activation of further platelets resulting in platelet aggregation and 
thrombus formation. The formation of a platelet plug by these processes is essential 
to seal vascular damages and to prevent blood loss. On the downside, thrombus 
formation under pathological conditions, such as upon rupture of an athero-
sclerotique plaque in stenosed vessels, can lead to irreversible occlusion and thereby 
to myocardial infarction or, if occurring in the brain, to stroke. Since these events 
represent leading causes of death in western societies, platelet inhibition is one 
major strategy to prevent or treat ischemic cardio- and cerebrovascular diseases. 
Platelet activation has to be tightly regulated to ensure efficient plug formation and 
wound healing on the one hand while, on the other hand, uncontrolled adhesion and 
activation has to be avoided. Therefore, platelets possess various adhesion 
receptors and ingenious regulation mechanisms in order to ensure controlled spatial 
and temporal activation. 
 
1.1 Platelet activation and thrombus formation 
Platelet activation and thrombus formation at sites of vascular injury involve multiple 
signaling processes, which can be divided into three major steps (Fig. 1). In the first 
step, platelets come into contact with the exposed ECM. Under conditions of high 
shear this contact, called “tethering”, is mediated by interaction between platelet 
glycoprotein (GP) Ib and von Willebrand Factor (vWF) immobilized on collagen of the 
ECM1. However, the GPIb-vWF interaction is not stable enough to allow firm 
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adhesion but rather serves to slow the platelets down, resulting in platelet “rolling” on 
the vessel wall.  
Enabled by the tethering process, in the second step of thrombus formation platelets 
bind to the ECM protein collagen via the platelet-specific immunoglobulin superfamily 
receptor glycoprotein (GP) VI2;3. This interaction triggers activation of platelet 
integrins and induces the release of secondary mediators, namely thromboxane A2 
(TXA2) and adenosine diphosphate (ADP). Together with thrombin produced at the 
site of injury, these mediators contribute to platelet activation by binding to G protein-
coupled receptors (Gq, G12/13, Gi), subsequently inducing full platelet activation4.  
In the third step, firm platelet adhesion on the ECM is mediated by active, high-
affinity 1 integrins, which bind to collagen (21), fibronectin (51) and laminin 
(61), as well as by the major platelet integrin, IIb3, which binds to fibronectin and 
vWF on the ECM. Finally, thrombus growth is induced by recruitment and activation 
of further platelets from the blood stream via released ADP and TXA2 and 
subsequent bridging of platelets via fibrinogen and vWF bound to integrin IIb3. 
 
 
 
 
 
 
 
Figure 1. Platelet activation and aggregation on the ECM. Interaction of GPIb with vWF 
immobilized on the ECM mediates platelet tethering and thereby enables GPVI to bind to exposed 
collagen. The GPVI-collagen interaction results in release of the secondary mediators ADP and TXA2, 
and the shift of platelet integrins to the activated high-affinity state, thereby mediating full platelet 
activation. In parallel, tissue factor (TF) locally induces thrombin formation which contributes to platelet 
activation. Activated platelet integrins mediate firm adhesion of platelets and thrombus growth by 
binding to ligands on the ECM (21, IIb3), as well as by bridging platelets via fibrinogen and vWF 
bound to IIb3. Taken from: Varga-Szabo D, Pleines I and Nieswandt B, Arterioscler Thromb Vasc 
Biol, 20085. 
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1.2 Integration of signaling events during platelet activation 
Platelets express a variety of receptors on the plasma membrane which, during the 
activation process, induce two major signaling pathways both leading to the 
activation of phospholipase (PL) C isoforms5.  
Soluble agonists such as thrombin, ADP and TXA2 stimulate receptors that couple to 
heterotrimeric G proteins (Gq) and lead to activation of phospholipase (PL) Cβ (Fig. 
2)6. Furthermore, G protein-coupled signaling stimulates activation of Rho GTPases 
which induce signaling pathways leading to cytoskeletal rearrangements and 
subsequent shape change and cell spreading4. 
The other pathway involves platelet adhesion receptors and culminates in activation 
of PLC2. In the initial phase of platelet activation, this pathway is triggered by 
activation of the collagen receptor GPVI7 or the C-type lectin-like receptor 2 (CLEC-
2), the receptor for the snake venom toxin rhodocytin (RC)8. Signaling induced by 
these receptors is similar to that used by immunoreceptors and involves tyrosine 
phosphorylation cascades downstream of the receptor-associated immunoreceptor 
tyrosine activation motif (ITAM) (GPVI) or YXXL motiv (CLEC-2) culminating in the 
activation of effector enzymes, most notably PLC2 (Fig. 2,8)9.  
In both cases, activated PLCs produce inositol 1,4,5-trisphosphate (IP3) and 
diacylglycerol (DAG) by cleavage of phosphatidyinositol-4,5-bisphosphate (PIP2). IP3 
then triggers Ca2+ mobilization from intracellular stores and subsequent opening of 
Ca2+ channels in the plasma membrane, leading to store operated Ca2+ entry 
(SOCE)5;10. DAG activates protein kinase C (PKC) and may contribute to Ca2+ entry 
by non-SOCE mechanisms11. Elevations in intracellular calcium concentration [Ca2+]i 
are a central step during platelet activation and a prerequisite for proper cellular 
responses including firm adhesion, as well as granule secretion and aggregation. 
Secretion of intracellular granules is crucial for the recruitment and activation of 
further platelets from the blood stream. Two different types of releasable granules 
exist in platelets:  granules contain various proteins including growth factors and 
thrombogenic proteins, such as thrombospondin, fibronectin and vWF. P-selectin 
expression on the platelet surface upon  granule release is one major degranulation 
marker and therefore widely used to assess the activation state of platelets in vitro. 
Dense granules contain small molecules, notably ADP and adenosine triphosphate 
(ATP), as well as histamine and serotonin12. Upon platelet activation with strong 
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agonists and a subsequent increase in [Ca2+]i, these granules are first centralized 
and then secreted13;14, thereby promoting platelet aggregation and thrombus growth.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2. Major signaling pathways in platelets. Two major signaling pathways exist in platelets. 
Soluble agonists activate G protein-coupled receptors (GPCRs). These agonists comprise secondary 
mediators released from activated platelets, such as TXA2, ADP, epinephrine and serotonin, as well as 
locally produced thrombin and induce various signaling pathways involving G12/13, Gq and Gi/z. 
Signaling downstream of Gq leads to activation of PLC. Furthermore, GPCRs induce activation of 
Rho GTPases leading to cytoskeletal rearrangements upon platelet activation. Adhesion receptors, 
such as the major platelet activating receptor GPVI, CLEC-2, active integrins and probably GPIb 
induce PLC2 activation upon ligand binding. PLCs cleave phosphatidyinositol-4,5-bisphosphate 
(PIP2) in DAG and IP3. IP3 and DAG induce and increase in cytosolic calcium, which is crucial for the 
platelet activatory response. Abbreviations: PI-3-K, phosphoinositide-3-kinase; Fg, fibrinogen; PIP3, 
phosphatidylinositol-3,4,5-trisphosphate; AC, adenylate cyclase; LAT, linker for activation of T cells. 
Modified from: Varga-Szabo D, Pleines I and Nieswandt B, Arterioscler Thromb Vasc Biol 20085. 
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1.3 Platelet elaboration from megakaryocytes 
Platelets are synthetized by precursor cells called megakaryocytes (MKs). MKs are 
myeloid cells which reside primarly in the bone marrow but are also found in spleen 
and lung. 
MKs differentiate from pluripotent hematopoietic stem cells (HSCs) that develop into 
two types of precursors: burst-forming cells (BFU) and colony-forming cells (CFU) 
(Fig. 3)15;16. Further development culminates in the formation of direct megakaryocyte 
precursors (CFU-Meg) which differentiate into megakaryocytes. Currently, 
thrombopoietin (TPO) is thought to be the primary regulator of thrombopoiesis, since 
it is the only cytokine required for MKs to constantly produce platelets17. TPO acts in 
concert with other cytokines, including interleukin (IL)-3, IL-6, IL-11, granulocyte 
macrophage colony-stimulating factor (GM-CSF) and stromal cell-derived factor-1 
(SDF-1), although these factors are not essential for MK maturation. Platelet factor 4 
(PF4) is a cytokine which is produced very late during megakaryopoiesis, 
predominantly in mature MKs. In addition to chemokines and cytokines, MK 
formation is tightly regulated by various transcription factors, most importantly NF-E2 
and GATA-118. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3:  
Regulation of megakaryopoiesis by 
cytokines and chemokines.  Left: A 
scheme based on the classical 
pathway of megakaryopoiesis is 
shown. Cytokines and chemokines that 
influence that process are depicted on 
the right side as green arrows to 
indicate the approximate level of 
development at which they have their 
influence. Open white areas in arrows 
indicate levels at which the cytokine is 
not known to act. Blue text refers to 
cytokine receptors of significance in 
megakaryopoiesis.  
Abbreviations: CFU, colony-forming 
unit; CFU-GEMM, CFU, granulocyte, 
erythrocyte, macrophage, megakary-
ocyte; CFU-EM, CFU, erythrocyte, 
megakaryocyte; BFU-EM, burstforming 
unit, erythrocyte, megakaryocyte; CFU-
Meg, CFU, megakaryocyte. Modified 
from: Pang L et al., JCI 200515. 
 
MKs are highly specialized for platelet biogenesis and their maturation is 
characterized by sequential steps19. First, MKs undergo multiple rounds of 
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endomitosis that amplifies the DNA up to 64-fold (modal ploidy: 16N in human and 
mice) and results in a polyploid, multi-lobed nucleus.  
In the next step, cytoplasmic maturation is initiated, including synthesis of platelet-
specific granules and organelles, as well as formation of a characteristic demarcation 
membrane system (DMS) that has continuity with the plasma membrane (Fig. 4b)18. 
At the end of this process, human MKs enlarge up to 100 µm in diameter (mice: 30-
50 µm) and are fully equipped with the elements necessary for platelet production. 
The exact mechanism of platelet biogenesis has been controversially discussed over 
the last decades. Some investigators supported the idea of a defragmentation model 
according to which mature MKs “burst” into thousands of platelets in the bone 
marrow. On the other hand, the flow model of platelet formation implies that mature 
MKs form pseudopodial extentions, so-called proplatelets, along which platelets are 
assembled (Fig. 4a). However, all recent studies using in vitro or in vivo imaging 
consistently report pseudopodia (proplatelet) formation from MKs as a common 
feature of platelet biogenesis, wherein the DMS seems to function as membrane 
reservoir for newly formed proplatelets20. In vitro, proplatelets are clearly visible 
structures, whereas in vivo, MKs display demarcation membrane invaginations 
resulting in so-called proplatelet territories (Fig. 4a,b). Very recent studies in vivo 
demonstrated that, under physiological conditions, mature MKs shed proplatelet-like 
structures into sinusoids of the bone marrow which are then further fragmentated to 
platelets by the shear forces present in blood vessels (Fig. 4b)21;22.  
Proplatelet formation from mature MKs involves multiple morphological changes. The 
importance of tubulin polymerization in this context is well established. Microtubule 
sliding does not only enable proplatelet elongation, but also mediates organelle 
trafficking into later platelets23;24. 
In contrast, little is known about the role of the actin cytoskeleton during 
megakaryocyte maturation and platelet biogenesis, although actin polymerization 
was shown to be involved in branching of proplatelets25. However, there is increasing 
evidence that signaling by small GTPases of the Rho family might play an important 
role in these processes.  
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Figure 4. Proplatelet formation from megakaryocytes. (a) Proplatelet formation in vitro. Left: After 
endomitosis and cytoplasmic maturation, the megakaryocyte forms pseudopodia which elongate into 
proplatelets. Sliding of overlapping microtubules drives proplatelet elongation and organelle trafficking 
into proplatelets. Bending and branching of the proplatelets serves to amplify ends. In the end of the 
process, the whole megakaryocyte is converted into a mass of proplatelets. Right: Differential 
interference contrast image of mouse proplatelets origined from one megakaryocyte. Bar, 5 µm. 
Modified from: Patel SR, Hartwig JH, Italiano JE, JCI 200525. (b) Proplatelet formation in bone marrow 
in vivo. Left: Mature megakaryocytes are situated in the vascular niche where molecules such as vWF 
induce proplatelet formation. Proplatelets cross the endothelial barrier and shear forces induce release 
of proplatelet fragments or individual platelets into the circulation. Right: Electron microscopy image of 
a mature megakaryocyte in the bone marrow. Note the presence of proplatelet territories (PTs) 
generated by the demarcation membrane system (DMS). Membrane invaginations and organelles are 
absent in the peripheral zone (PZ) of mature megakaryocytes. Bar, 5 µm. Modified from: Bluteau D et 
al., JTH 200926 and Eckly A et al., Blood 200927. 
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1.4 Small GTPases of the Rho family 
Rho GTPases are small (20-25 kDa) members of the superfamily of Ras-related 
proteins which are found in all eukaryotic cells28 and are best known for their 
functions in regulation of the actin cytoskeleton.  
The family of mammalian Rho GTPases comprises 20 members in total, the most 
widely known being RhoA, Rac1 and Cdc42. Most Rho GTPases cycle between a 
guanosine triphosphate (GTP)-bound, active, and a guanosine diphosphate (GDP)-
bound, inactive form (Fig. 5). Cycling between the two activation states is regulated 
by guanine nucleotide exchange factors (GEFs), GTPase-activating proteins (GAPs) 
and guanine nucleotide-dissociation inhibitors (GDIs). In the active, GTP-bound form, 
Rho GTPases bind to their effector molecules, thereby inducing multiple processes, 
including cell adhesion, division and migration, as well as vesicle transport and 
microtubule dynamics. Furthermore, they participate in the regulation of 
morphogenesis, cell cycle progression and gene expression28. 
 
Figure 5.  
Activation cycle of Rho GTPases. 
Rho GTPases cycle between an 
inactive, GDP-bound and an active, 
GTP-bound state which allows 
binding of effector molecules. 
Exchange from GDP to GTP is 
mediated by GEFs, whereas GAPs  
mediate inactivation of Rho GTPases 
by increasing their intrinsic GTPase 
activity. GDIs bind to C-terminal 
prenyl groups of some GTPases, 
sequestering them away from their 
regulators. 
 
 
 
 
 
 
 
 
Much knowledge about the roles of Rho GTPases has been gained by 
overexpression studies in cell lines using dominant negative or constitutively active 
Rho proteins to either inhibit or overstimulate the respective signaling pathways. 
However, many of those studies yielded conflicting results often caused by unspecific 
side effects of the used reagents.  
Therefore, the recent generation of (conditional) knock-out mice for several GTPases 
has provided new tools to reliably study the effect of GTPase deficiency with a 
minimal risk of secondary effects29.  
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1.4.1 Rho GTPases in platelets and the hematopoietic system 
Platelet activation at sites of vascular injury induces multiple cytoskeletal 
rearrangements including a change from discoid to spheric shape (the so-called 
“shape change”), and eventually adhesion to and spreading on immobilized ligands 
or matrices, such as fibrinogen or collagens. Whereas RhoA activation in platelets 
has been shown to be essential for stress fiber formation and platelet shape 
change30;31, Cdc42 and Rac1 have been suggested to induce the formation of 
filopodia and lamellipodia, respectively32;33.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 6. Rho GTPases mediate cytoskeletal rearrangements in activated platelets. (a) 
Characteristic scanning electron microscopy images of activated platelets forming lamellipodia and 
filopodia, as well as visualization of stress fibers. Bar, 1 µm (Nieswandt and Gachet, personal results). 
The role of Cdc42 for filopodia formation in platelets is questioned in this study. (b) Scanning electron 
microscopy images of resting platelets (left) or activated platelets in suspension (right). Resting 
platelets have a discoid shape whereas activated platelets in suspension are of spheric shape and 
form numerous filopodia. Bar, 2 µm (Nieswandt and Gachet, personal results). 
 
Platelet filopodia and lamellipodia formation can be nicely visualized by static 
adhesion assays e.g. spreading on matrices, such as collagen or fibrinogen (Fig. 6a). 
Platelets activated in suspension exhibit profound shape change and the formation of 
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numerous filopodia (Fig. 6b). An overview of signaling events leading to lamellipodia 
and filopodia formation by Rac1 and Cdc42 is shown in Fig. 729. 
Although the crucial role of Rho GTPases for the regulation of actin rearrangements 
in platelets is well established, more recent studies indicate that the GTPases 
participate in many additional signaling pathways during the process of platelet 
activation. Furthermore, their function in megakaryocyte and platelet formation is 
largely unclear. This thesis focuses on the role of the Rho GTPases Rac1 and Cdc42 
for platelet function and production using conditional knock-out mice. 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 7. Formation of filopodia and lamellipodia by Cdc42 and Rac1. Cdc42 can bind and 
activate Wiscott-Aldrich syndrome protein (WASP) or the insulin-receptor substrate p53 (IRSp53) Tyr 
Kinase which results in activation of the actin-related protein (ARP)2/3 complex, thereby inducing actin 
polymerization and filopodia formation. Rac1 activates the ARP2/3 complex through the WASP-family 
verprolin-homologous protein (WAVE) complex. Both Rac1 and Cdc42 can also induce actin 
polymerization by activation of the formin mammalian diaphanous-2 (mDia2). Activation of Ser/Thr 
p21-activated kinase (PAK) by Rac1 or Cdc42 leads to phosphorylation of LIM kinase (LIMK) which 
phosphorylates and inhibits cofilin, thereby decreasing actin turnover. Modified from: Heasman SJ and 
Ridley AJ, Nature Reviews 200829. 
 
1.4.2 Rac1 
The subfamily of Rac GTPases comprises three isoforms (Rac1, 2, 3). Rac1 and 3 
are widely expressed, whereas Rac2 expression is restricted to hematopoietic cells. 
Constitutive deletion of Rac1 in mice leads to embryonic lethality before embryonic 
day (E) 9.534. Rac1 is best known for its ability to induce lamellipodia formation in 
various cell types. In the hematopoietic system, knock-out studies showed that Rac1 
was not required for the maintentance of steady-state hematopoiesis, however, it 
was essential for engraftment of hematopoietic stem cells (HSCs) after bone marrow 
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transplantation in mice in vivo35. Further studies demonstrated an important and 
redundant role for Rac1 and Rac2 during early B and T cell development, so that 
deficiency of Rac1 alone had no effect on maturation of these cells36-38. 
Of the three Rac isoforms, only Rac1 has been found to be expressed in detectable 
amounts in platelets33. Rac1 activation in platelets downstream of G-protein coupled 
receptor (GPCR) stimulation, e.g. by thrombin, is well established39-42 (Fig. 2) and 
previous studies have indicated that Rac1 may become activated downstream of 
integrin IIb3, thereby regulating lamellipodia formation43. This was recently 
confirmed by McCarty et al. in Rac1-deficient murine platelets who in addition 
observed an unexplained selective impairment of GPVI-, but not GPCR-induced 
aggregation (Fig. 8)33. In contrast to that study, Akbar et al. reported a general 
secretion defect in Rac1-deficient murine platelets and in human platelets treated 
with a selective Rac1 inhibitor44. 
Several studies demonstrated Rac1 activation after GPVI/ITAM stimulation. However, 
Rac1 activation in this context was mostly suggested to occur not directly but as a 
second step after release of secondary mediators and subsequent induction of G 
protein-coupled signaling42;45. Interestingly, using heterologous cell systems and cell-
free assays, Piechulek et al. have shown that Rac1 may be involved in the activation 
of PLC2 by a mechanism independent of tyrosine phosphorylation of the enzyme, 
thereby providing a possible direct link between GPVI signaling and Rac1 activity46. 
However, the role of Rac1 downstream of ITAM-coupled receptor activation in 
platelets has not been analyzed in detail. 
Figure 8. The GPVI signaling 
pathway. GPVI is non-covalently 
associated with the Fc receptor- 
(FcR) chain which bears an 
immunoreceptor tyrosine activation 
motif  (ITAM). Activation of GPVI 
by collagen-binding induces 
tyrosine phosphorylation of the 
ITAM and SYK. Subsequently a 
phosphorylation cascade is 
initiated which involves several 
adaptor proteins, including LAT 
and SLP-76, and results in 
activation of the effector protein 
PLC. PLC induces the gene-
ration of DAG and IP3 resulting in 
Ca2+ mobilization. The role of Rac1 
downstream of GPVI activation is 
unclear. 
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1.4.3 Cdc42 
Cdc42 is ubiquitously expressed and was first identified in yeast as a cell cycle-
regulating protein. In mammalian cells, however, the GTPase has been shown to be 
involved in a variety of signaling processes including actin cytoskeletal 
reorganization, gene transcription, cell proliferation and differentiation47. Constitutive 
deletion of Cdc42 in mice leads to death of the embryos before E 7.548.  
In the hematopoietic system, recent reports using conditional knock-out mice 
revealed a crucial role for Cdc42 in regulating the balance between myelopoiesis and 
erythropoiesis, as well as for B cell development and activation and regulation of 
neutrophil polarity49-51. Further studies reported a role for the GTPase in macrophage 
chemotaxis and phagocytosis52;53 and migration of monocytes54.  
Cdc42 has been demonstrated to be an important mediator of filopodia formation in 
various cell types. However, recent studies suggest that filopodia formation can also 
occur independently of Cdc42, involving most notably the novel Rho GTPase Rho-in 
filopodia (Rif) and the lipid-phosphatase-related protein-1 (LPR1)55;56. Importantly, 
genetic targeting demonstrated that Cdc42 is not required for filopodia formation in 
embryonic fibroblastoid cells57. 
In addition to filopodia formation, Cdc42 has also been shown in several studies to 
be crucially involved in exocytosis in different cell types, such as neuroendocrine58;59 
and MIN6 beta cells60-62, as well as endothelial cells63;64. Furthermore, in the 
hematopoietic system, Cdc42 activation was postulated to be essential for mediation 
of antigen-stimulated degranulation in RBL mast cells65;66. 
Despite a number of previous studies on the function of Cdc42 in platelets, its role in 
platelet activation and cytoskeletal reorganization, as well as its impact on 
degranulation and thrombus formation is currently unclear.  
 
1.4.4 Rho GTPases in megakaryopoiesis and platelet biogenesis 
As already mentioned, there is still little known about the impact of actin cytoskeletal 
rearrangements during megakaryocyte maturation and platelet production in general 
and the importance of Rho GTPases in particular.  
Inhibition of the Rab GTPase Rab27b in primary MKs resulted in abrogated 
proplatelet formation while MK differentiation and ploidy remained unaltered67. 
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Recently, overexpression studies revealed a negative regulation of proplatelet 
formation by RhoA in vitro68. In line with this, modification of RhoA downstream 
effector pathways by inhibition of myosin light chain (MLC) phosphorylation or MLC II, 
as well as megakaryocyte-specific deletion of MYH9, the main myosin heavy chain, 
resulted in increased proplatelet formation27;69. Although the function of Rac1 in 
megakaryocyte maturation and platelet production has not been studied in detail, it is 
assumed that the GTPase is dispensable for these processes since platelet count 
and size were normal in Rac1 conditional knock-out mice. In contrast, the role of 
Cdc42 during megakaryocyte maturation and platelet biogenesis is largely unknown. 
 
1.5 Aim of the study 
Cytoskeletal rearrangements play a crucial role during platelet shape change, 
secretion and spreading and small GTPases of the Rho family have been reported to 
be importantly involved in these processes. However, although a large number of 
studies address the function of Rho GTPases in various cell types, their role for 
platelet function is still largely unclear. 
The aim of this thesis was (I) to investigate the function of the Rho GTPases Rac1 
and Cdc42 for platelet function and signaling and (II) to gain new insights into their 
role for platelet production from megakaryocytes. For this purpose, conditional knock-
out mice were generated using the Cre/loxP system with two different promoter 
strategies and analysis of single-, as well as double-deficient mice was performed. 
 
2  Materials and methods 
2 MATERIALS AND METHODS 
 
2.1 Materials 
2.1.1 Kits and reagents 
acetic acid      Roth (Karlsruhe, Germany) 
ADP        Sigma (Deisenhofen, Germany)  
agarose      Roth (Karlsruhe, Germany) 
agarose, low melting              Euromedex (France) 
ammonium peroxodisulphat (APS)  Roth (Karlsruhe, Germany) 
apyrase (grade III)      Sigma (Deisenhofen, Germany) 
atipamezol                                                         Pfizer (Karlsruhe, Germany) 
ATP release kit                                                  Roche Diagnostics (Mannheim) 
avertin (2,2,2-tribromoethanol              Sigma(Deisenhofen, Germany) 
and 2-methyl-2-butanol) 
beta-mercaptoethanol    Roth (Karlsruhe, Germany) 
bovine serum albumin (BSA)   AppliChem (Darmstadt, Germany) 
calcium chloride     Roth (Karlsruhe, Germany) 
Complete mini protease inhibitors (+EDTA) Roche Diagnostics (Mannheim) 
convulxin                      Alexis Biochemicals (San Diego, USA) 
Dylight-488                                                        Pierce (Rockford, IL,USA)   
Dynal Mouse T cell negative isolation kit          Invitrogen (Karlsruhe, Germany) 
EDTA       AppliChem (Darmstadt, Germany) 
enhanced chemoluminiscence (ECL)  PerkinElmer LAS (Boston, USA) 
detection substrate  
dNTP mix             Fermentas (St. Leon-Rot, Germany) 
eosin                                                                  Roth (Karlsruhe, Germany) 
epinephrine                        Sigma (Deisenhofen, Germany) 
epon 812                          Roth (Karlsruhe, Germany) 
ethanol      Roth (Karlsruhe, Germany) 
ethidium bromide     Roth (Karlsruhe, Germany) 
Eukitt mounting medium       Sigma (Deisenhofen, Germany)      
fat-free dry milk     AppliChem (Darmstadt, Germany) 
fentanyl                                                             Janssen-Cilag GmbH  
                                                                          (Neuss, Germany) 
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fibrilar type I collagen (Horm)   Nycomed (Munich, Germany) 
flumazenil                                                          Delta Select GmbH  
                                                                          (Dreieich, Germany) 
fluorescein-isothiocyanate (FITC)   Molecular Probes (Oregon, USA) 
Fura-2 acetoxymethyl ester (AM)                      Molecular Probes (Oregon, USA) 
gelatine capsules                                              Agar scientific (Stansted, England) 
GeneRuler 1kb DNA Ladder   Fermentas (St. Leon-Rot, Germany) 
glucose      Roth (Karlsruhe, Germany) 
glutaraldehyde                           Roth (Karlsruhe, Germany) 
hematoxylin      Sigma (Deisenhofen, Germany)         
HEPES      Roth (Karlsruhe, Germany) 
Hexomethyldizilasin (HMDS)   Merck  (Darmstadt, Germany) 
high molecular weight heparin    Sigma (Deisenhofen, Germany) 
human fibrinogen      Sigma (Deisenhofen, Germany) 
human vWF        CSL Behring (Hattersheim, Germany) 
igepal CA-630     Sigma (Deisenhofen, Germany) 
indomethacin                Sigma (Deisenhofen, Germany) 
Integrilin                                          GlaxoSmithKline (Germany) 
IP1 ELISA kit                                       Cisbio (Paris, France) 
isopropanol      Roth (Karlsruhe, Germany) 
6x Loading Dye Solution    Fermentas (St. Leon-Rot, Germany) 
magnesium chloride    Roth (Karlsruhe, Germany) 
medetomidine                                                    Pfizer (Karlsruhe, Germany)  
midazolam                                                         Roche Pharma AG  
                                                                          (Grenzach- Wyhlen, Germany) 
mouse PF4 ELISA kit                   RayBiotech (Georgia, USA) 
mouse P-selectin ELISA kit                  RayBiotech (Georgia, USA) 
naloxon                                                              Delta Select GmbH  
                                                                          (Dreieich, Germany) 
osmic acid solution 2%                                  Merck (Darmstadt, Germany) 
for electron microscopy 
PageRuler Prestained Protein Ladder  Fermentas (St. Leon-Rot, Germany) 
paraformaldehyde                               Roth (Karlsruhe, Germany) 
phalloidin-FITC                                  Sigma (Deisenhofen, Germany) 
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phenol/chloroform/isoamylalcohol            AppliChem (Darmstadt, Germany) 
phorbol 12-myristate 13-acetate (PMA)   Sigma (Deisenhofen, Germany) 
pI-pC                                               GE Healthcare (Buckinhamshire, 
                                                                           England) 
Pluronic F-127                                            Invitrogen (Karlsruhe, Germany)  
Poly-L-lysine                         Sigma (Deisenhofen, Germany) 
potassium acetate     Roth (Karlsruhe, Germany) 
prostacyclin       Calbiochem (Bad Soden, Germany) 
R-phycoerythrin (PE)                                         EUROPA (Cambridge, UK) 
Rotiphorese Gel 30 (PAA)    Roth (Karlsruhe, Germany) 
Serotonin ELISA kit                                           IBL (Hamburg, Germany) 
sodium chloride     AppliChem (Darmstadt, Germany) 
sodium cacodylate     Roth (Karlsruhe, Germany) 
tannic acid                    Merck (Darmstadt, Germany) 
Taq polymerase           Fermentas (St. Leon-Rot, Germany) 
Taq polymerase buffer (10x)        Fermentas (St. Leon-Rot, Germany) 
TEMED      Roth (Karlsruhe, Germany) 
3,3,5,5-tetramethylbenzidine (TMB)   EUROPA (Cambridge, UK) 
thapsigargin                                                       Molecular Probes (Oregon, USA) 
thrombin       Roche Diagnostics (Mannheim) 
triton X-100      AppliChem (Darmstadt, Germany) 
uranyl acetate                Ladd Research Industries (USA) 
U46619       Alexis Biochemicals (San Diego, USA) 
 
Collagen-related peptide (CRP) was kindly provided by S.P. Watson (University of 
Birmingham, UK). Rhodocytin was a generous gift from Johannes Eble (University 
Hospital Frankfurt, Germany). Botrocetin was kindly provided by Francois Lanza 
(EFS Alsace, Strasbourg, France). All other chemicals were obtained from Sigma 
(Deisenhofen, Germany) or Roth (Karlsruhe, Germany). 
 
2.1.2 Cell culture materials 
BSA, low endotoxin                PAA Laboratories (Cölbe, Germany) 
DMEM + GlutaMAX-I    Gibco (Karlsruhe, Germany) 
D-PBS      Gibco (Karlsruhe, Germany) 
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Foetal Bovine Serum (FCS)   Gibco (Karlsruhe, Germany) 
IMDM + GlutaMAX-I    Gibco (Karlsruhe, Germany) 
Penicillin-Streptomycin     Gibco (Karlsruhe, Germany) 
Steritop Bottle Top Filter 0.22 µm  Millipore (Massachusetts, USA) 
thrombopoietin                                  Invitrogen (Karlsruhe, Germany) 
tissue culture dishes (100x20 mm)  BD Falcon (Bedford, USA) 
well plates (6-well, 24-well or 96-well)  BD Falcon (Bedford, USA) 
 
2.1.3 Antibodies 
2.1.3.1 Purchased primary and secondary antibodies 
CD3 antibody                                          BD Biosciences  
                                            (Heidelberg,Germany) 
CD11b antibody                                     BD Biosciences  
CD45R/B220  antibody                          BD Biosciences 
Cdc42 antibody                            BD Biosciences  
cofilin antibody                            Cell Signaling Technologies (USA) 
hFibrinogen  antibody                                        DAKO (Hamburg, Germany) 
hvWF antibody                                              DAKO (Hamburg, Germany)  
Ly-6G and Ly-6C  antibody                         BD Biosciences  
PLC2 antibody clone Q20                                Santa Cruz Biotechnologies (USA)  
phosphocofilin antibody                                     Cell Signaling Technologies (USA) 
phosphotyrosine antibody clone 4G10              Upstate (CA, USA) 
Rac1 antibody                                          BD Biosciences  
RFc (CD16/CD32/FcIII/II) antibody                  DAKO (Hamburg, Germany) 
Ter119 antibody                                    BD Biosciences                                                     
 
hvWF-HRP antibody                                  DAKO (Hamburg, Germany) 
hFibrinogen-FITC antibody                                DAKO (Hamburg, Germany) 
rabbit anti-FITC-HRP antibody                       DAKO (Hamburg, Germany)                                  
rat anti-mouse IgG-HRP                                    DAKO (Hamburg, Germany)        
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2.1.3.2 Monoclonal Antibodies (mAbs) 
mAbs generated and modified in our laboratory: 
 
antibody isotype antigen described in 
JAQ1 IgG2a GPVI 70 
DOM2 IgG1 GPV 71 
JON/A IgG2b GPIIb/IIIa 72 
JON1 IgG2a GPIIb/IIIa 71 
ULF1 IgG2a CD9 71 
p0p4 IgG2b GPIb 71 
p0p6 IgG2b GPIX 71 
MWReg 30 IgG1 2 integrin Unpublished 
12C6 IgG2b 2 integrin Unpublished 
WUG1.9 IgG1 P-selectin Unpublished 
 
 
2.1.4 Animals 
Mice with floxed Rac173 or Cdc42 genes74 were kindly provided by Cord Brakebusch 
(Copenhagen, Denmark). Transgenic mice carrying either the Mx-Cre transgene (Mx-
cre+)75 or the PF4-Cre transgene (PF4-Cre+)76 were from Cord Brakebusch and 
Radek Skoda (Basel, Switzerland), respectively.  
For the Mx-Cre strategy, gene deletion was induced in 5 to 6 week-old ((fl/fl)/Mx-
cre+) mice (25-30 g body weight) by two intraperitoneal injections of 200 µg 
polyinosinic-polycytidylic acid (pI-pC) in a two-day interval. Control mice ((fl/fl)/Mx-
cre-) received the same treatment and were derived from the same litters. Ten days 
after the last injection, the mice were tested for successful knock-out by western blot 
analysis of platelet lysates. For experiments, mice were used at least 2 weeks after 
pI-pC injection. In case of the PF4-Cre strategy, gene deletion occurred intrinsically 
upon activation of the PF4 promoter during megakaryopoiesis. 
All used mice were maintained on a mixed SV/129/C57/Bl-6 background. Animal 
studies were approved by the district government of Lower Franconia 
(Bezirksregierung Unterfranken).   
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2.1.5 Buffers and media 
All buffers were prepared and diluted using aqua ad iniectabilia (DeltaSelect 
Pfullingen, Germany) or double-distilled water (ddH2O). 
 
Acid-citrate-dextrose (ACD) buffer, pH 4.5 
                trisodium citrate dehydrate    85 mM 
                citric acid anhydrous     65 mM 
                glucose anhydrous     110 mM 
 
Blocking solution for immunoblotting 
BSA or fat-free dry milk     5% 
in PBS or washing buffer 
 
Blotting buffer A for immunoblotting 
TRIS, pH 10.4       0.3 M 
methanol       20% 
 
Blotting buffer B for immunoblotting 
TRIS, pH 10.4                 25 mM 
           methanol                 20% 
 
Blotting buffer C for immunoblotting 
-amino-n-caproic acid, pH 7.6   4 mM 
methanol                                                                 20% 
 
Cacodylate buffer (electron microscopy), pH 7.2 
sodium cacodylate     50 mM 
 
CATCH buffer (modified) 
HEPES          25 mM 
EDTA               3 mM 
           BSA                            3.5% 
           in PBS, pH 7.2 
 
Coating buffer (ELISA), pH 9.0 
NaHCO3                                     50 mM 
       
Coomassie staining solution 
acetic acid       10% 
methanol       40% 
Coomassie Brilliant blue     0.01% 
 
Coomassie destaining solution 
acetic acid       10% 
methanol       40%  
 
Decalcification buffer 
EDTA              10% 
in PBS, pH 7.2 
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Fixation buffer I (electron microscopy) 
                sodium cacodylate, pH 7.2           0.1 M 
                glutaraldehyde        2.5% 
                formaldehyde          2% 
 
Fixation buffer II (electron microscopy) 
                sodium cacodylate, pH 7.2           50 mM 
                osmium tetroxid      2% 
     
IP buffer 
TRIS/HCl, pH 8.0     15 mM 
NaCl        155 mM 
EDTA        1 mM  
NaN3        0.005% 
 
Laemmli buffer for SDS-PAGE 
TRIS        40 mM 
glycine       0.95 M 
SDS        0.5% 
 
Lysis buffer (DNA isolation), pH 7.2 
TRIS base       100 mM 
EDTA             5 mM 
NaCl        200 mM 
SDS        0.2% 
add Proteinase K (20 mg/ ml)    100 µg/ml 
 
Lysis buffer (tyrosine phosphorylation), pH 7.5  
NaCl              300 mM 
TRIS                20 mM 
EGTA       2 mM 
EDTA       2 mM 
Na3VO4                                                                             2 mM 
Igepal CA-630                  2% 
add complete mini protease inhibitors                                                                           
 
MK Medium 
IMDM  
FCS        10% 
Penicillin-Streptomycin     1% 
TPO                           50 ng/ml 
 
Permeabilization buffer (electron microscopy) 
Taxol                                10-5 M  
Triton X-100                   0.75%  
Phalloidin                                10-6 M 
PFA                              0.1% 
add PHEM (pH 7.2) and complete mini protease inhibitors 
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PHEM, pH 7.2 
PIPES                                     60 mM  
HEPES                          25 mM  
EGTA                                  10 mM 
MgSO4                                    2 mM  
 
Phosphate buffered saline (PBS), pH 7.14 
NaCl        137 mM  
KCl        2.7 mM  
KH2PO4        1.5 mM 
Na2HPO4                  8 mM 
 
Propidium iodide staining solution 
propidium iodide                                            25 µg/ml 
RNase                                    100 µg/ml 
in PBS, pH 7.2 
 
SDS sample buffer, 2x 
-mercaptoethanol (for reduced conditions)  10% 
TRIS buffer (1.25 M), pH 6.8     10% 
glycerine       20% 
SDS        4% 
bromophenolblue      0.02%  
 
Separating gel buffer, pH 8.8 
TRIS/HCl       1.5 M 
 
Stacking gel buffer, pH 6.8 
TRIS/HCl       0.5 M 
 
Stripping buffer, pH 6.8 
TRIS/HCl                                                            62.5 mM 
SDS                                                   2% 
-mercaptoethanol     100 mM 
 
50x TAE 
TRIS       0.2 M 
acetic acid       5.7% 
EDTA (0.5 M, pH 8)     10% 
 
TE buffer, pH 8 
TRIS base      10 mM 
EDTA                                                                 1 mM 
        
Tris-buffered saline (TBS), pH 7.3 
                NaCl                                     137 mM  
TRIS/HCl                                    20 mM 
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Tyrode´s buffer, pH 7.3 
NaCl         137 mM  
KCl                        2.7 mM  
                NaHCO3                       12 mM 
                NaH2PO4                                                       0.43 mM 
                CaCl2                                                               1 mM 
                MgCl2                                                                1 mM 
                HEPES                                                             5 mM 
                BSA                                                                  0.35% 
                glucose                                                               0.1% 
                 
Washing buffer (western blot) 
Tween 20       0.1%  
in PBS, pH 7.2 
 
 
 
2.2 Methods 
2.2.1 Mouse genotyping 
2.2.1.1 Isolation of genomic DNA from mouse ears  
An approximately 5 mm2 part of one ear was dissolved in 500 μl DNA lysis buffer by 
overnight incubation at 56°C under shaking conditions (900 rpm). 500 µl 
phenol/chloroform were added and, after vigorous shaking, samples were centrifuged 
at 14000 rpm for 10 min at room temperature (RT). Approximately 450 µl supernatant 
were taken and transferred into a new tube containing 500 µl isopropanol. After 
vigorous shaking, samples were centrifuged at 14000 rpm for 10 min at 4°C. The 
resulting DNA pellet was washed with 500 µl of 70% ethanol and centrifuged at 
14000 rpm for 10 min at 4°C. After a second washing step, the DNA pellet was left to 
dry and finally resuspended in 100 µl TE buffer. Genotyping by PCR was performed 
using 2 µl DNA solution and 20 µl PCR reaction were separated on agarose gels for 
analysis. 
 
2.2.1.2 Sample preparation for PCR 
The pipeting scheme shown is representative for 1 sample (final volume: 50 µl) for 
the below described genotyping PCRs. 
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 2 µl DNA solution 
5 µl 10x Taq buffer 
5 µl MgCl2 (25 mM) 
2 µl dNTPs (10 µM) 
2 µl primer 1 1:10 (stock: 1 µg/µl) 
2 µl primer 2 1:10 (stock: 1 µg/µl) 
0.5 µl Taq polymerase 
31.5 µl H2O 
 
 
 
 
 
 
 
 
2.2.1.3 Detection of the Cdc42 floxed allele by PCR 
 Primers 
      Cdc42_for   5’ ATG TAG TGT CTG TCC ATT GG 3’ 
      Cdc42_rev  5’ TCT GCC ATC TAC ACA TAC AC 3’ 
 
 PCR program 
95°C      2:00 min 
 
95°C      0:30 min 
63°C      0:30 min    10x 
(-1 °C each cycle)    
72°C      0:45 min     
 
95°C      0:30 min 
53°C      0:30 min    35x 
72°C      0:45 min 
 
72°C      4:00 min    
4°C        ∞   
 
 Resulting band sizes 
wt allele       :  200 bp 
floxed allele :  300 bp 
 
2.2.1.4 Detection of the Rac1 floxed allele by PCR 
 Primers 
Rac1_for   5’ GTC TTG AGT TAC ATC TCT GG 3’ 
Rac1_rev   5’ CTG ACG CCA ACA ACT ATG C 3’ 
 
 PCR program 
95°C      5:00 min 
 
95°C      0:30 min 
63°C      0:30 min    10x 
(-1 °C each cycle)    
72°C      0:30 min     
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95°C      0:30 min 
53°C      0:30 min    35x 
72°C      0:30 min 
 
72°C      7:00 min    
4°C        ∞   
 
 Resulting band sizes  
wt allele       :  236 bp 
floxed allele :  318 bp 
 
 
2.2.1.5 Detection of the Mx-Cre transgene by PCR 
 Primers 
Mx-Cre_for   5’ AAC ATG CTT CAT CGT CGG 3’ 
Mx-Cre_rev  5’ TTC GGA TCA TCA GCT ACA CC 3’ 
 
 PCR program 
95°C      3:00 min 
 
95°C      0:30 min 
63°C      0:30 min    10x 
(-1 °C each cycle)    
72°C      0:30 min     
 
95°C     0:30 min 
53°C      0:30 min    35x 
72°C      0:30 min 
 
72°C      7:00 min    
4°C        ∞   
 
 Resulting band sizes  
wt                      :  no PCR product 
Mx-Cre+            :  400 bp 
 
 
2.2.1.6 Detection of the PF4-Cre transgene by PCR 
 Primers 
PF4-Cre_for   5’ CCC ATA CAG CAC ACC TTT G 3’ 
PF4-Cre_rev  5’ TGC ACA GTC AGC AGG TT 3’ 
 
 PCR program 
96°C      3:00 min 
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94°C      0:30 min 
58°C      0:30 min    35x 
72°C      0:45 min 
 
72°C      3:00 min  
4°C        ∞      
 
 Resulting band sizes 
wt             :  no PCR product 
PF4-Cre+ :  450 bp 
 
 
2.2.2 In vitro analysis of platelet function 
2.2.2.1 Platelet preparation and washing 
Mice were bled under isofluran anesthesia from the retroorbital plexus. 700 µl blood 
were collected into an Eppendorf tube containg either 300 μl heparin in TBS (20 
U/ml, pH 7.3) or 300 µl acid citrate dextrose (ACD). Blood was centrifuged at 1800 
rpm for 5 min at RT. Supernatant and buffy coat were transferred into a new tube and 
centrifuged at 800 rpm for 6 min at RT to obtain platelet rich plasma (prp). To prepare 
washed platelets, prp was centrifuged at 2500 rpm for 5 min at RT in the presence of 
prostacyclin (PGI2) (0.1 μg/ml) and the pellet was resuspended in 1 ml Ca2+-free 
Tyrode’s buffer containing PGI2 (0.1 μg/ml) and apyrase (0.02 U/ml). After 10 min 
incubation at 37°C the sample was centrifuged at 2500 rpm for 5 min. After a second 
washing step, the platelet pellet was resuspended in 500 µl Tyrode’s buffer 
containing apyrase (0.02 U/ml) and left to incubate for at least 30 min at 37°C before 
analysis. 
 
2.2.2.2 Platelet counting  
For determination of platelet count and size, 50 µl blood were drawn from the 
retroorbital plexus of anesthetized mice using heparinized microcapillaries and 
collected into an Eppendorf tube containing 300 μl heparin in TBS (20 U/ml, pH 7.3). 
Platelet counts and size were determined using a Sysmex KX-21N automated 
hematology analyzer (Sysmex Corp., Kobe, Japan). 
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2.2.2.3 Immunoblotting 
For western blot analysis, prp was prepared as described in section 2.2.2.1. Prp was 
centrifuged at 2500 rpm for 5 min and platelets were washed twice in PBS + 5 mM 
EDTA. The final platelet pellet was resuspended in IP buffer containing protease 
inhibitors to a final concentration of at least 0.5x106 platelets/µl and Igepal was added 
to a final concentration of 1%. After incubation for 20 min at 4°C and centrifugation at 
14000 rpm for 5 min, the supernatant was mixed with an equal amount of 2x SDS 
sample buffer and boiled at 95°C for 5 min. Samples were separated by 12 or 15% 
SDS-PAGE and transferred onto a polyvinylidene difluoride (PVDF) membrane. To 
prevent non-specific antibody binding, membranes were blocked in 5% fat-free milk 
or 5% BSA dissolved in washing buffer for 2 h at RT or over night (o/n) at 4°C. 
Membranes were incubated with the required primary antibody (5 μg/ml) o/n at 4°C 
with gentle shaking. Afterwards membranes were washed three times with washing 
buffer for 15 min at RT under shaking conditions. Next, membranes were incubated 
with appropriated HRP-labeled secondary antibodies for 1 h at RT. After three 
washing steps, proteins were visualized by ECL. 
 
2.2.2.4 Flow cytometry  
For determination of glycoprotein expression levels, platelets (1x106) were stained for 
10 min at RT with saturating amounts of fluorophore-conjugated antibodies described 
in section 2.1.3.2, and analyzed directly after addition of 500 µl PBS. For activation 
studies, platelets were activated with appropriate agonists or reagents for 15 min at 
RT in the presence of saturating amounts of phycoerythrin (PE)-coupled JON/A and 
fluorescein isothiocyanate (FITC)-coupled P-selectin antibodies. The reaction was 
stopped by addition of 500 μl PBS and samples were analyzed on a FACSCalibur 
(Becton Dickinson, Heidelberg, Germany). For a two-colour staining, the following 
settings were used: 
 
Detectors/Amps: 
Parameter Detector Voltage 
P1 FSC E01 
P2 SSC 380 
P3 Fl1 650 
P4 Fl2 580 
P5 Fl3 150 
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Threshold: 
Value Parameter 
253 FSC-H 
52 SSC-H 
52 Fl1-H 
52 Fl2-H 
52 Fl3-H 
 
Compensation: 
Fl1 2.4% of Fl2 
Fl2 7.0% of Fl1 
Fl2 0% of Fl3 
Fl3 0% of Fl2 
 
 
2.2.2.5 Aggregometry and agglutination 
Washed platelets were adjusted to a concentration of 0.3x106 platelets/ml with 
Tyrode’s buffer. Alternatively, heparinized prp was used and diluted 1:3 in Tyrode´s 
buffer. For determination of aggregation, agonists or reagents (100-fold 
concentrated) were added and light transmission was recorded over 10 min on an 
Apact 4-channel optical aggregation system (APACT, Hamburg, Germany). 
Agglutination was induced in washed platelets by addition of 5 µg/ml botrocetin and 
10 µg/ml human vWF in the presence of 40 µg/ml Integrilin. For calibration of each 
measurement before agonist addition, Tyrode’s buffer (for washed platelets) or 1:3-
diluted plasma (for prp) was set as 100% aggregation and washed platelet 
suspension or prp was set as 0% aggregation. 
 
2.2.2.6 Static adhesion assays 
2.2.2.6.1 Adhesion on human fibrinogen or collagen-related peptide 
Glass coverslips were coated with 100 µg human fibrinogen or 100 µg/ml collagen-
related peptide (CRP) (diluted in PBS) overnight at 4°C under humid conditions and 
blocked for 2 h at RT with PBS 2% BSA. The coverslips were rinsed with Tyrode´s 
buffer and washed platelets (100 µl with 0.03x106 platelets/µl) were added and 
incubated at RT for the indicated time periods. The coverslips were rinsed again with 
Tyrode´s buffer and platelets were visualized with a Zeiss Axiovert 200 inverted 
microscope (x100) using differential interference contrast (DIC) microscopy. 
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Representative images were taken and evaluated according to different platelet 
spreading stages. 
 
2.2.2.6.2 Adhesion on murine vWF 
Glass cover slips were coated with a polyclonal rabbit anti-human von Willebrand 
Factor (vWF) antibody (6.2 µg/ml, DAKO) for 2 h at 37°C under humid conditions and 
incubated with 10 µg/ml of mouse recombinant vWF for 2 h at RT. The coverslips 
were blocked for 1 h at RT with PBS 1% BSA. 300 µl of washed platelets at 0.03x106 
platelets/µl were incubated with Integrilin (40 µg/ml) and botrocetin (2 µg/ml) and 
were allowed to adhere on the prepared coverslips for 20 min at 37°C. Samples were 
rinsed with PBS, fixed with 2.5% glutharaldehyde and processed for scanning 
electron microscopy (SEM). 
 
2.2.2.7 Intracellular calcium measurements  
Washed platelets at a concentration of approximately 0.4x106 platelets/µl in Ca2+-free 
Tyrode´s buffer were loaded with fura-2 AM (5 μM) in the presence of Pluronic F-127 
(0.2 μg/ml) for 30 min at 37°C. After labeling, platelets were washed once and 
resuspended in Tyrode’s buffer containing either 1 mM Ca2+ (for measurement of 
SOCE) or no Ca2+ (for measurement of store release). Stirred platelets were 
activated with appropriate agonists or reagents and fluorescence was measured with 
a PerkinElmer LS 55 fluorimeter. Excitation was alternated between 340 and 380 nm, 
and emission was measured at 509 nm. Each measurement was calibrated using 1% 
Triton X-100 and EGTA. 
 
2.2.2.8 Adhesion under flow conditions  
Coverslips (24 x 60 mm) were coated with 200 µg/ml fibrilar type-I collagen (Horm) 
o/n at 37°C and blocked for 1 h with 1% BSA. Blood (700 μl) was collected into 300 
μl TBS (pH 7.3) containing 20 U/ml heparin and platelets were labeled with a Dylight-
488 conjugated anti-GPIX Ig derivative (0.2 μg/ml) for 5 min at 37°C. Two parts of 
blood were diluted with 1 part Tyrode´s buffer and filled into a 1 ml syringe. Perfusion 
studies were performed as follows. Transparent flow chambers with a slit depth of 50 
µm, equipped with the coated coverslips, were connected to the syringe filled with 
diluted whole blood. Perfusion was performed using a pulse-free pump under high or 
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low shear stress equivalent to a wall shear rate of 1000 s-1 or 150 s-1 (4 min and 10 
min). Thereafter, coverslips were washed by a 4 min perfusion with Tyrode’s buffer at 
the same shear stress and phase-contrast and fluorescent images were recorded 
from at least five different microscope fields (40x objective). Image analysis was 
performed off-line using MetaVue® software. Thrombus formation was expressed as 
the mean percentage of total area covered by thrombi, and as the mean integrated 
fluorescence intensity per mm2. 
 
2.2.2.9 Measurement of platelet nucleotide content and ATP release  
For determination of platelet nucleotide contents, washed platelets were 
resuspended in Ca2+-free Tyrode´s buffer and proteins were precipitated with ice-cold 
6.6 N perchloric acid. After centrifugation, nucleotides were isolated from 
supernatants with trioctylamine and freon (vol/vol) and measured by HPLC. For 
determination of ATP release washed platelets were adjusted to a concentration of 
0.4x106/µl. Platelets were activated with the indicated agonists for 2 min at 37°C 
under stirring conditions (1000 rpm). Following activation, EDTA (3 mM final 
concentration) and formaldehyde (0.1% final concentration) were added and platelets 
were fixed for 2 h. The platelets were then centrifuged for 1 min at 13,000 rpm and 
100 µl supernatant were added to 100 µl absolute ethanol. Samples were stored at -
20°C until measuring. Levels of ATP in 12.5 µl sample were quantified using a 
bioluminescence assay kit according to the manufacturers´ instructions and a 
Fluostar Optima luminometer (BMG Lab Technologies, Germany). 
 
2.2.2.10  Measurement of  platelet  P-selectin,  vWF  and  serotonin  content and  
              serotonin release 
For determination of platelet P-selectin and vWF content, washed platelets at a 
concentration of 0.4x106 platelets/µl were lysed in IP buffer containing 1% Igepal, 
incubated for 30 min at 4°C and centrifuged 5 min at 14000 rpm. P-selectin content 
was determined using a mouse P-selectin ELISA according to the manufacturers´ 
protocol. For determination of vWF content, ELISA plates were coated with 10 µg/ml 
rabbit anti-human vWF antibody in coating buffer o/n at 4°C and blocked with TBS 
0.1% Tween 5% BSA. A log2 dilution of the samples in blocking buffer was prepared 
in the plate and incubated 2h at 37°C. After washing with TBS 0.1% Tween, samples 
were incubated with HRP-coupled rabbit anti-human antibody (1:3000 in blocking 
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buffer). After washing, ELISAs were developed using TMB-one substrate and plates 
were read at 450 nm. For determination of platelet serotonin content washed 
platelets were prepared as described above and lysed by two repeated freezing-
thawing cycles using liquid nitrogen. After centrifugation for 5 min at 14000 rpm, the 
serotonin content in 10 µl s/n was determined using a human serotonin ELISA kit 
according to the manufacturers´ protocol. For determination of serotonin release 
washed platelets were activated with the indicated agonists for 2 min at 37°C, 
immediately centrifuged 1 min at 10000 rpm and the serotonin concentration in 10 µl 
s/n was measured by ELISA. 
 
2.2.2.11 Measurement of IP1 
Washed platelets were adjusted to a concentration of 0.7x106/µl in a modified 
phosphate-free Tyrode´s buffer containing 2 mM Ca2+ and 50 mM LiCl2. Apyrase, 
indomethacin and EDTA were added to a final concentration of 2 U/ml, 10 µM and 5 
mM, respectively. Platelets were activated with the indicated agonists for 5 min at 
37°C (350 rpm). After stimulation, platelets were lysed in the buffer supplied by the IP 
one ELISA kit (Cisbio, Paris, France). 50 µl of lysed platelets were used for the IP1 
ELISA assay according to the manufacturers´ protocol. 
 
2.2.2.12 Tyrosine phosphorylation and immunoprecipitation 
For tyrosine phosphorylation studies, equal amounts of platelets from wild-type and 
knock-out animals in suspension (0.7x106 platelets/µl) were stimulated with 2.5 µg/ml 
convulxin under stirring conditions (1000 rpm) at 37°C. Stimulation was stopped by 
the addition of an equal volume ice-cold lysis buffer. For whole-cell tyrosine-
phosphorylation, Laemmli’s sample buffer was added; samples were incubated at 
95°C for 5 min and separated by SDS-PAGE on 4-12% pre-cast NuPage Bis-Tris 
gradient gels (Invitrogen, Karlsruhe, Germany) under reducing conditions followed by 
transfer onto a PVDF membrane. For immunoprecipitation of individual proteins, 
following platelet lysis, samples were incubated with 2 µg anti-PLC2 antibody for 1 h 
at 4°C on a rotor and subsequently with Protein G-Sepharose at 4°C o/n. 
Immunoprecipitated proteins were washed three times in IP buffer before being 
boiled in Laemmli’s sample buffer at 95°C for 5 min. Proteins were separated by 
SDS-PAGE on 4-12% pre-cast NuPage Bis-Tris gradient gels under reducing 
conditions followed by transfer onto a PVDF membrane. Membranes were blocked 
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for 1 h in 5% BSA in PBS and then incubated with the anti-phosphotyrosine antibody 
4G10 for 1 h at RT. The membranes were then washed 4x 15 min in washing buffer 
before being incubated with secondary anti-mouse horseradish peroxidase-
conjugated antibody in washing buffer. Following extensive washing, the membranes 
were developed using an enhanced chemiluminescence detection system. For 
tyrosine phosphorylation studies of individual proteins, membranes were incubated 
for 35 min at 50°C in stripping buffer and reprobed with anti-PLC2 antibody. Western 
blots were developed like described above. 
 
2.2.2.13 Determination of platelet filamentous (F)-actin content 
Washed platelets were prepared and the platelet count was adjusted to 0.2x106 
platelets/µl in Ca2+-freeTyrode´s buffer. Platelets were diluted 1:10 in Tyrode´s buffer 
in a final volume of 50 µl per condition, 5 µl Dylight 649-conjugated anti-GPIX Ig 
derivative were added and samples were incubated 3 min at 37°C. Next, platelets 
were stimulated with 1 U/ml thrombin (final concentration) for 2 min at 37°C (400 
rpm) and fixed for 10 min at 37°C by addition of 0.55% volume 10% PFA in PBS. 
Samples were centrifuged 5 min at 2500 rpm, the pellet was resuspended in 55 µl 
Tyrode´s buffer containing 0.1 volume % Triton-X 100 and 50 µl were mixed with 
phalloidin-FITC at a final concentration of 10 µM. Samples were incubated 30 min at 
RT in the dark and the reaction was stopped by addition of 500 µl PBS. Samples 
were centrifuged 5 min at 2500 rpm and the pellet was resuspended in 500 µl PBS. 
Samples were put on ice and immediately analyzed using a FACSCalibur (Beckton 
Dickinson, Heidelberg, Germany). 
 
2.2.3 In vivo analysis of platelet function 
2.2.3.1 Determination of platelet life span  
Mice were injected intravenously with a Dylight-488 conjugated anti-GPIX Ig 
derivative (0.5 µg/g body weight). At 1 h after injection (day 0), as well as at the other 
indicated time points, 50 µl blood were collected and the percentage of GPIX-positive 
platelets was determined by flow cytometry.  
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2.2.3.2 Bleeding time assay 
Mice were anesthetized and a 2 mm segment of the tail tip was removed with a 
scalpel. Tail bleeding was monitored by gently absorbing blood with filter paper at 20 
second intervals, without directly contacting the wound site. When no blood was 
observed on the paper, bleeding was determined to have ceased. Experiments were 
stopped after 20 minutes. 
 
2.2.3.3 Intravital microscopy of thrombus formation in FeCl3-injured 
mesenteric arterioles 
Mice (4-5 weeks of age) were anesthetized, and the mesentery was exteriorized 
through a midline abdominal incision. Arterioles (35-60 µm diameter) were visualized 
with a Zeiss Axiovert 200 inverted microscope (x10) equipped with a 100-W HBO 
fluorescent lamp source, and a CoolSNAP-EZ camera (Visitron, Munich, Germany). 
Digital images were recorded and analyzed off-line using Metavue software. Injury 
was induced by topical application of a 3 mm2 filter paper saturated with FeCl3 (20%). 
Adhesion and aggregation of fluorescently labeled platelets (Dylight-488 conjugated 
anti-GPIX Ig derivative) in arterioles was monitored for 40 min or until complete 
occlusion occurred (blood flow stopped for >1 min). 
 
2.2.3.4 Monitoring of platelet adhesion to the injured carotid artery by intravital 
microscopy  
Anesthetized mice were injected with carboxyfluorescein succinimidyl ester (CFSE)-
labeled platelets of donor mice of the same genotype. The carotid artery was injured 
through ligation using a surgical filament and adhesion of platelets to the vessel wall 
was monitored over 10 min by fluorescence microscopy in vivo.  
 
2.2.3.5  Intravital microscopy of thrombus formation in the abdominal aorta 
The abdominal aorta of anesthetized mice was mechanically injured by a firm (5 sec) 
compression with a forceps and blood flow was monitored using an ultrasonic flow 
probe for 45 min or until full occlusion.  
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2.2.4 Megakaryocyte (MK) analysis 
2.2.4.1 Isolation of MKs from fetal liver, purification by BSA gradient and study 
of proplatelet formation 
Embryos of embryonic day (E) 13.5-14.5 were obtained from time-mated females, 
livers were removed, transferred into 1 ml pre-warmed DMEM and the remaining part 
of the body was kept in PBS and used for genotyping. Liver cells were resuspended 
10x each using 19G and 22G needles and a 1 ml syringe and the cell suspension 
was centrifuged 5 min at 900 rpm (RT). The cells were resuspended in 2 ml MK 
medium, divided into 2 wells of a 12-well plate and incubated at 37°C, 5% CO2. At 
day 3 of culture, MKs were purified by a BSA gradient following the protocol of 
Shivdasani et al.77 and the isolated MKs were resuspended in 1 ml MK medium. For 
analysis of proplatelet formation, appr. 3000 cells/well were cultured in 96-well platels 
(triplicates) for one additional day and the percentage of proplatelet-forming MKs per 
visual field (20x objective) was determined. The remaining cells were cultured in one 
well of a 12-well plate for further analysis.  
 
2.2.4.2 Isolation and culture of MKs from bone marrow of adult mice 
Femurae and tibiae of adult (approximately 6 week-old) mice were isolated and the 
bone marrow was flushed out using 2 ml modified CATCH buffer. Cells were 
homogenized using 23G needles and a 1 ml syringe and filtered through a cell 
strainer (40 µm, Falcon, Bedford, USA). The cell strainer was washed using 8 ml 
modified CATCH buffer and cells were counted using a Neubauer Chamber. MKs 
were purified by negative selection with the Dynal mouse T cell negative isolation kit 
according to the manufacturers´ protocol using anti-B220, anti-GR-1 (Ly-6G/C), anti-
CD3, anti-Ter-119 and anti-Mac1 antibodies (1:50 dilution). For this, the cells were 
centrifuged 10 min at 1200 rpm (RT) and the pellet was resuspended in PBS to a 
concentration of 100x106 cells/ml. Antibodies and washed magnetic beads were 
added and the cells were incubated 20 min at RT with gentle shaking. Afterwards, 
the beads were washed with three times PBS using a magnetic rack and the washing 
fractions were collected. Cells were counted and centrifuged 10 min at 1200 rpm 
(RT). For analysis of proplatelet formation, the cells were plated on 96-well plates at 
a concentration of 5000 cells/well in MK medium, incubated for 4-6 days at 37°C, 5% 
CO2, and proplatelet formation was analyzed as described above. The remaining 
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cells were cultured in 6-well plates at a concentration of 0.25x106 cells/well for further 
analysis. 
 
2.2.4.3 Determination of MK ploidy by flow cytometry 
When using fetal liver, fetal liver cells were cultured for 3 days as described 2.2.4.1 
and used directly. Femurae and tibiae of adult mice were isolated and bone marrow 
was flushed out using 2 ml modified CATCH buffer. 200 µl of the suspension were 
transferred into a FACS tube and centrifuged 5 min at 1200 rpm (RT) One additional 
sample was prepared for the isotype control. Cells were resuspended in 400 µl 1:1 
mixture CATCH/PBS 5% FCS. For saturation of unspecific binding sites, all samples 
were incubated with anti-RFc (CD16/CD32 FcIII/II) antibody (1:50 dilution) for 15 
min on ice. Staining of GPIIb was directly afterwards performed using a FITC-
conjugated anti-2 integrin (GPIIb) Ig derivative (5D7-FITC) at a 1:2.5 dilution for 20 
min on ice. The isotype control was incubated with anti-rat IgG1-FITC under the 
same conditions. For washing, 1 ml 1:1 mixture CATCH/PBS 5% FCS were added 
and samples were centrifuged 5 min at 1200 rpm (RT). For fixation, cells were 
resuspended in 250 µl PBS 0.1% EDTA, mixed well, an equal volume PBS 1% PFA 
was added and samples were incubated 10 min on ice. Cells were washed by 
addition of 3 ml PBS and centrifugation for 10 min at 1200 rpm (RT). For 
Permeabilization, cells were resuspended in 500 µl PBS 0.1% Tween, incubated 10 
min on ice and washed as described above. Cells were resuspended in 500 µl 
propidium iodide (PI) staining solution, stained over night at 4°C in the dark and 
analyzed using a FACSCalibur (Becton Dickinson). For analysis, the GPIIb/PI-
positive population was gated and the mean ploidy of the different ploidy stages was 
determined. 
 
2.2.5 Electron microscopy 
2.2.5.1 Transmission electron microscopy (TEM) of MKs in situ 
For transmission electron microscopy the femura of mice were cut into approximately 
1.5 mm pieces and fixed for 3 hours or over night at 4°C with fixation buffer I. The 
bone was removed with forceps and the bone marrow was washed with cacodylate 
buffer and subsequently fixed for 2 hours at 4°C with fixation buffer II. Samples were 
washed with distilled water and stained over night with 0.5% aqueous uranyl acetate, 
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dehydrated with ethanol and embedded in Epon 812. Ultrathin sections were stained 
with 2% uranyl acetate (in 100% ethanol) followed by lead citrate as described78. 
Sections were inspected with an EM900 electron microscope (Zeiss, Oberkochen, 
Germany). Negatives were digitalized by scanning and processed with Adobe 
Photoshop.  
 
2.2.5.2 TEM of platelets in suspension 
Washed platelets were adjusted to a concentration of 0.3x106 platelets/µl in Tyrode´s 
buffer. Platelets were activated with 0.1 U/ml thrombin or 5 µM ADP (final 
concentration) under stirring conditions at 37°C and fixed by additon of an equal 
amount cacodylate buffer containing 5% glutaraldehyde for 10 min at 37°C without 
stirring. For complete fixation samples were incubated for 1 h at RT and afterwards at 
4°C until further processing. Next, a small amount of the sample was further diluted 
to 1:10 in cacodylate buffer and washed three times by addition of 1 ml cacodylate 
buffer and subsequent centrifugation for 5 min at 1000 g (RT). Platelets were then 
left to adhere 1 h on poly-L-lysine-coated coverslips and processed for scanning 
electron microscopy (see 2.2.5.3). The remaining samples were washed three times 
for 5 min by addition of 1 ml cacodylate buffer and subsequent centrifugation for 5 
min at 1500 g (37°C). A 2% low melting agarose solution in cacodylate buffer was 
prepared and kept at 45°C. After the final washing step, platelets were resuspended 
carefully in 1 ml agarose solution and immediately centrifuged 5 min at 14000 rpm 
(37°C). All except 100 µl agarose solution were discarded and samples were 
incubated on ice for 10 min. The hardened agarose pellets were cut out of the tubes 
and the platelet pellets were cut into approximately 1 mm2 pieces and stored in 
cacodylate buffer. Samples were fixed in cacodylate buffer containing 1% OsO4 for 
45 min - 1 h at RT, washed twice with ddH2O and incubated 60 min at 4°C in 2% 
uranylacetate in ddH2O. After three washing steps with ddH2O, samples were 
dehydrated in 70% (4x5 min), 95% (3x15 min) and 100% (3x15 min) ethanol. Next 
samples were incubated first in 100% propylenoxyde (2x10 min) and then in a 1:1 
mixture propylenoxyde/epon (1x60 min) under rotating conditions. After 2 further 
incubations in epon at RT (first step: over night, second step: 2-3 h) samples were 
embedded in gelatine capsules and left to dry for 48 h at 60%. 50 nm thin sections 
were cut using a ultra microtom (Leica Ultracut UCT), contrasted and analyzed 
(Philips). 
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2.2.5.3 Scanning electron microscopy (SEM) of platelets 
For immobilization and visualization of platelets fixed in suspension, coverslips were 
coated with 0.01% poly-L-lysine for 15 min at RT and left to dry over night at RT. 
Fixed platelets (see 2.2.5.2) were left to adhere for 20 min - 1h and further processes 
as described below.  
For static adhesion, roundish coverslips (12 mm diameter) were coated with 100 
µg/ml human fibrinogen in PBS for 2 h at RT, blocked 1 h with 1% BSA in PBS and 
shortly washed with PBS. Washed platelets were adjusted to a concentration of 
0.03x106 platelets/µl, activated with 0.01 U/ml thrombin and 100 µl were immediately 
added to the coverslips and incubated at 37°C for the indicated time points. Samples 
were fixed by addition of 300 µl cacodylate buffer containing 2.5% glutaraldehyde for 
1 h at 37°C and 1 h at RT and kept at 4°C until further processing. Coverslips were 
washed twice with 200 µl cacodylate buffer and dehydrated in 70% (4x5 min), 80% 
(1x5 min), 95% (1x5 min) and 100% (2x30 min) ethanol. Next, the coverslips were 
incubated with increasing concentrations of hexomethyldizilasin (HMDS) in 100% 
ethanol (25%: 1x 5 min; 50%: 1x5 min; 75%: 1x5 min, 100%: 2x5 min). Samples 
were left to dry, sputtered with gold using a Cressington Sputter Coater 108 Auto and 
a 0.2 µm thin gold foil (both from Cressington, Chalk Hill, England) and analyzed 
using a FEI electron microscope (Philips). 
 
2.2.5.4 Visualization of the platelet cytoskeleton by SEM 
Washed platelets were ajusted to a concentration of 0.03x106 platelets/µl, activated 
and incubated on fibrinogen-coated coverslips as described in section 2.2.5.3. 
Afterwards, the coverslips were immediately treated with 500 µl permeabilization 
buffer for 2 min at 37°C. Reactions were stopped by addition of the same volume 
PHEM containing 4% PFA and 0.4% glutaraldehyde and incubated 1 h at RT and 
afterwards over night at 4°C. Coverslips were next washed in PHEM (1x), ddH2O 
(5x), 0.2% aqueous tannic acid (1x2 min), ddH2O (5x), 0.5% OsO4 (1x5 min) and 
ddH2O (5x). Subsequently, coverslips were dehydrated and further processed for 
SEM as described above. 
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2.2.6 Histology 
2.2.6.1 Preparation of paraffin sections 
Spleen and femurs from adult mice were washed in PBS and fixed over night in PBS 
4% PFA. Afterwards, organs were washed 3 times with PBS and spleens were 
directly dehydrated and embedded in paraffin. Fixed femurs were incubated for 3 
further weeks in 10 ml decalcification buffer with the buffer being changed twice per 
week. After decalcification, femurs were also embedded in paraffin. Organs were cut 
using a Microm Cool Cut microtom (Thermo Scientific, Braunschweig, Germany) to 
prepare 5 µm thin sections. 
 
2.2.6.2 Hematoxylin/eosin staining of paraffin sections 
Sections were deparaffinated by two incubations in Xylol (3 min each). Rehydration 
was carried out using decreasing ethanol concentrations (100, 96, 90, 80 and 70%) 
with 2 incubation time in each solution and a final 2 min incubation in deionized 
water. Next, sections were stained 2 min with hematoxylin, followed by a 10 min 
washing step using running tab water and 2 min staining with 0.05% Eosin G. The 
sections were washed shortly and dehydration was carried out using the same 
ethanol concentrations and incubation times as described above, but in reversed 
order. Finally sections were incubated twice in Xylol for each 3 min, dried and 
mounted using Eukitt mounting medium. Samples were analyzed using a Leica DHI 
4000B inverse microscope equipped with a Leica digital camera. 
 
2.2.7 Data analysis 
Results are shown as mean ± SD from at least three individual experiments per 
group. Statistical analysis between wild-type and knock-out groups were assessed by 
the Mann-Whitney U-test. P-values <0.05 were considered statistically significant.  
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3 RESULTS 
 
3.1 Rac1 is essential for phospholipase C-2 activation in platelets 
3.1.1 Rac1 is dispensable for platelet production but essential for lamellipodia 
formation 
Lack of functional Rac1 leads to embryonic lethality in mice34. Since at the time of the 
study, PF4-Cre mice were not available, conditional knock-out mice were generated 
by using the Mx-Cre/loxP system73;75. Deletion of the Rac1 gene in Rac1 (fl/fl cre+) 
mice was induced by repeated injections of pI-pC which induces Cre expression in 
the hematopoietic system and leads to efficient gene deletion in megakaryocytes 
and, consequently, protein deficiency in platelets2;79. Rac1 (fl/fl) mice not carrying Mx-
Cre were used as wild-type controls. Ten days after the last injection, the absence of 
Rac1 in platelets from Rac1 (fl/fl cre+, further referred to as Rac1-/-) mice was 
confirmed by Western blot analysis of whole cell lysates (Fig. 9a) using GPIIIa levels 
as loading control.  
 
wild-type Rac1-/-   
454 ± 28 403 ± 23 GPIb  
 
290 ± 6 262 ± 6 GPV 
 
486 ± 27 470 ± 17 GPIX 
 
45 ± 6 40 ± 3 GPVI 
 
118 ± 4 113 ± 10 2 
171 ± 2 185 ± 29 1 
 586 ± 44 545 ± 59 IIb3 
 1260 ± 214 1080 ± 49 CD9 
 mean FSC 
 
Deletion of Rac1 had no significant effect on peripheral platelet counts (Fig. 9b) or 
the expression of prominent surface receptors including integrins IIb3 and 21 as 
well as GPIb and GPVI (Table 1). In line with this, the life span of Rac1-/- platelets 
was comparable to wild-type platelets (Fig. 9c). These results strongly indicated that 
Rac1 is not essential for megakaryocyte development and platelet production.  
560 ± 35 455 ± 43 
Table 1. Platelet membrane 
glycoprotein expression in Rac1-/- 
platelets. Diluted whole blood was 
stained with fluorophore-labeled 
antibodies at saturating concentrations 
for 15 min at RT and analyzed on a 
FACSCalibur (Becton Dickinson, 
Heidelberg). Platelets were gated by 
FSC/SSC characteristics. Results are 
given as the mean fluorescence 
intensity ± SD of 6-12 mice per group. 
Mean platelet size (mean FSC) was 
determined by FSC characteristics. 
(Pleines I et al., Pflugers Arch 200980.) 
Furthermore, in accordance with the proposed function of Rac143, Rac1-/- platelets 
failed to form lamellipodia and to spread on a fibrinogen coated surface upon 
thrombin stimulation, but retained the ability to adhere and form filopodia, confirming 
recent results from McCarty et al.33 (Fig. 9d). 
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Figure 9. Rac1 is dispensable for platelet production but essential for lammelipodia formation. 
(a) Western blot analysis of Rac1 expression in wild-type and Rac1-/- platelets 10 days after the first 
pI-pC injection. GPIIIa was used as control. (b) Peripheral platelet counts (n=6 per group). (c) Rac1-/- 
platelets have a normal life span. Wild-type (black) and Rac1-/- mice (gray) were injected intravenously 
with Dylight-488 conjugated anti-GPIX Ig derivative (0.5 µg/g body weight) and the population of 
fluorescently labeled platelets was monitored over 5 days using flow cytometry. (d) Washed platelets 
from the indicated mice were allowed to adhere and spread on immobilized human fibrinogen upon 
thrombin activation. DIC images taken at t=45 min, representative of 6 individual experiments. Bar, 5 
µm. (Pleines I et al., Pflugers Arch 200980.) 
 
3.1.2 Scanning electron microscopy studies of Rac1-/- platelets 
To study the morphology of Rac1-/- platelets in more detail, scanning electron 
microscopy (SEM) was performed. The results confirmed unaltered size of resting 
platelets, as compared to wild-type platelets (Fig. 10a), as well as the inability of 
Rac1-/- platelets to form lamellipodia on fibrinogen upon thrombin activation (Fig. 10b, 
upper panel). Visualization of the cytoskeleton of activated platelets by SEM 
demonstrated the presence of actin stress fibers in wild-type platelets, whereas 
Rac1-/- platelets were only able to form filopodia (Fig. 10b, lower panel). In contrast, 
when activated in suspension with ADP or thrombin, Rac1-/- and wild-type platelets 
exhibited similar morphology (Fig. 10c). This result indicated that lamellipodia 
formation may rather be of importance for platelet spreading on ligand-covered 
surfaces, such as the ECM, than for platelet aggregation in the flowing blood.  
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Figure 10. Scanning electron microscopy studies of Rac1-/- platelets. (a–c) Scanning electron 
microscopy (SEM) of Rac1-/- and wild-type platelets. (a) resting platelets immobilized on poly-L-lysine. 
Bar, 5 µm. (b) Spread Rac1-/- and wild-type platelets upon activation with 0.01 U/ml thrombin on 
human fibrinogen (100 µg/ml, 30 min). Upper panel: SEM of intact platelets. Lower panel: visualization 
of the actin cytoskeleton after denudation of the plasma membrane. Bar, 2 µm. (c) Morphology of 
Rac1-/- and wild-type platelets in suspension at 15 seconds after activation with thrombin (0.1 U/ml, 
upper panel) or ADP (5 µM, lower panel). Bar, 1 µm. 
 
 
3.1.3 Rac1-/- platelets show diminished responses to GPVI and CLEC-2 
stimulation 
The response of Rac1-/- platelets to different agonists was tested by standard 
aggregometry. In response to thrombin, ADP, and the stable TXA2 analog U46619 
Rac1-/- platelets aggregated normally at all tested concentrations (Fig. 11a,d), 
although a slightly faster reversion of ADP-induced aggregation was consistently 
observed with mutant platelets as compared to the wild-type controls. In contrast, 
Rac1-/- platelets showed a clear reduction in their reactivity towards collagen which 
was most evident at low and intermediate concentrations of the agonist (Fig. 11b,d).  
 40
3  Results 
Since platelet activation by collagen is mediated by GPVI, in the next step, a possible 
defect in this pathway was tested by use of the GPVI-specific agonist collagen 
related peptide (CRP). Again, a markedly reduced response was found in Rac1-/- 
platelets that was most evident at low and intermediate concentrations (Fig. 11b,d). 
Interestingly, rhodocytin (RC)-induced aggregation was also impaired at low and 
intermediate concentrations, suggesting defective signaling downstream of CLEC-
28;81. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 11. Rac1-/- platelets show impaired aggregation responses to GPVI agonists. Washed 
platelets from wild-type (black line) and Rac1-/- (gray line) mice were activated with the indicated 
concentrations of (a) ADP, U46619 and thrombin, (b) collagen and CRP or (c) rhodocytin. The 
experiments were performed in the presence of 70 µg/ml human fibrinogen. Thrombin stimulation was 
done in the absence of human fibrinogen. The results shown are representative of 9-15 individual 
experiments. (d) Bar graphs of results obtained by aggregometry. Results are given as the mean % of 
aggregation ± SD. (Pleines I et al., Pflugers Arch 200980.) 
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It is well established that under conditions of standard aggregometry, aggregation in 
response to collagen, and to a lower extent also to CRP, is amplified by released 
mediators, such as ADP and TXA2, making it difficult to directly assess defects in 
individual signaling pathways. Therefore, platelets were pre-incubated with apyrase 
(2 U/ml) and indomethacin (10 µM) to prevent the effects of these mediators and then 
stimulated with high concentrations of collagen (20 µg/ml) or CRP (10 µg/ml). Under 
these conditions, wild-type but not Rac1-/- platelets were able to aggregate, strongly 
indicating a selective GPVI signaling defect in the absence of Rac1 (Fig. 12).  
 
 
 
 
 
 
 
 
Figure 12. Aggregation of Rac1-/- platelets upon GPVI stimulation is abolished in presence of 
inhibitors of secondary agonists. (a) Washed platelets from wild-type (black line) and Rac1-/- (gray 
line) mice were incubated with high concentrations of apyrase (2 U/ml) and indomethacin (10 M) and 
activated with the indicated concentrations of collagen and CRP. The experiments were performed in 
the presence of 70 µg/ml human fibrinogen. The results shown are representative of 4 individual 
experiments. (b) Bar graphs of results obtained by aggregometry. Results are given as the mean % of 
aggregation ± SD. (Pleines I et al., Pflugers Arch 200980.) 
 
The results of aggregometry were confirmed by flow cytometric analysis of single 
platelets in diluted suspensions, i.e. under experimental conditions that largely 
exclude the accumulation of released mediators82;83. Washed platelets were 
stimulated with increasing concentrations of CRP, RC, thrombin and ADP and the 
activation of integrin IIb3 (JON/A-PE72), as well as degranulation-dependent 
surface exposure of P-selectin was determined. Equally strong IIb3 activation was 
observed in control and Rac1-/- platelets in response to thrombin and ADP (Fig. 
13a,c). Likewise, thrombin-induced P-selectin expression was indistinguishable 
between the two groups at all tested concentrations (Fig. 13b,c), whereas ADP, as 
expected, failed to induce significant P-selectin expression. In contrast, the response 
of Rac1-/- platelets to CRP or the GPVI-activating snake venom protein convulxin 
(CVX) was virtually abolished, even at very high concentrations of the agonists. 
Similarly, IIb3 activation and P-selectin expression were dramatically impaired in 
 42
3  Results 
response to RC in Rac1-/- platelets. This selective secretion defect was also 
confirmed when ATP release was determined. Thrombin induced comparable ATP 
release in control and Rac1-/- platelets, whereas CRP- or CVX-induced ATP release 
was minimal in the mutant cells (Fig. 13d).  
Together, these results demonstrate a pronounced defect in Rac1-/- platelets in the 
ITAM and ITAM-like signaling pathways mediated by GPVI and CLEC-2, 
respectively, but normal responses to G protein-coupled agonists.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 13. Defective IIb3 activation and granule secretion in Rac1-/- platelets in response to 
GPVI and CLEC-2 stimulation. Washed blood from wild-type and Rac1-/- mice was incubated for 15 
min with the indicated agonists in the presence of JON/A-PE directed against the activated form of 
mouse IIb3 and a FITC-conjugated anti-mouse P-selectin antibody. Data shown are mean 
fluorescence intensities (MFI) ± SD (n=6 per group) for (a) JON/A-PE and (b) anti-P-selectin-FITC. (c) 
Representative dot plots (Fl1/Fl2). (d) Measurement of released ATP. Washed platelets were 
incubated for 2 min at 37°C with the indicated agonists and fixed. ATP present in the supernatant was 
measured using a luminometric assay. Results are given as mean ATP concentration (M) ± SD (n=6 
per group). (Pleines I et al., Pflugers Arch 200980.) 
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3.1.4 Defective PLC2 activation and Ca2+ mobilization in Rac1-/- platelets  
The results shown above suggested that Rac1 might be directly involved in 
ITAM/ITAM-like signaling upstream of Ca2+ mobilization and PKC activation as these 
processes were obviously functional downstream of Gq-coupled agonists. To test this 
directly, changes in [Ca2+]i in response to thrombin and CRP were assessed. As 
shown in Fig. 14a and b, intracellular Ca2+ mobilization in response to CRP was 
significantly reduced in Rac1-/- platelets compared to controls as determined in the 
absence of extracellular Ca2+. As a direct consequence, the subsequent Ca2+ entry 
was also dramatically diminished in the mutant cells. In contrast, unaltered Ca2+ 
mobilization and entry was seen in response to thrombin stimulation. These results 
suggested that Rac1 may be required for efficient activation of PLC2, but not PLC.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 14. Defective calcium mobilization upon GPVI stimulation in Rac1-/- platelets. (a) Time 
course of intracellular calcium mobilization in wild-type (black curve) and Rac1-/- platelets (gray curve) 
in response to thrombin (0.1 U/ml) and CRP (5 µg/ml) in the presence (1 mM Ca2+) and absence (5 
mM EGTA) of extracellular Ca2+. Results shown are representative of 6 individual experiments. (b) 
Maximal increase of cytosolic Ca2+ concentration of wild-type (black bars) and Rac1-/- platelets (gray 
bars) after activation with the indicated agonists. Results are given as mean Ca2+i (nM) ± SD, n=3 
per group. (Pleines I et al., Pflugers Arch 200980.) 
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To test this more directly, PLC2 activity was analyzed by indirect measurement of 
inositol trisphosphate (IP3) using an IP1 ELISA (Fig. 15a). The IP3 lifetime within the 
cell is very short (less than 30 sec) before it is transformed into IP2 and IP1. IP1 can 
accumulate in the cell after addition of Li+ ions which inhibits its degradation to myo-
inositol. Therefore, IP1 was quantified after platelet activation with thrombin (1 U/ml) 
or CVX (1 µg/ml) in the presence of apyrase (2 U/ml) and indomethacin (10 µM). 
While thrombin-induced IP1 production was comparable in control and Rac1-/- 
platelets, the response to CVX was markedly reduced in the mutant cells as 
compared to controls (137 ± 17 nM vs. 418 ± 37.1 nM, n=3, P<0.001), indicating that 
the activity of PLC2 was indeed affected in the absence of Rac1 (Fig. 15a).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 15. Defective GPVI- induced PLC2 activation in Rac1-/- platelets. (a) Quantification of 
produced IP1 upon activation. Washed platelets from wild-type and Rac1-/- mice were stimulated with 
the indicated agonists. Platelets were lysed and IP1, a specific metabolite of IP3, was quantified using 
an ELISA assay. Results are given as the mean IP1 concentration (nM) ± SD (n=3 per group). (b) 
Determination of tyrosine phosphorylation. Washed platelets from wild-type and Rac1-/- mice were 
stimulated with 1 g/ml CVX and aliquots were taken at the indicated time points. Samples were 
blotted and stained using an antibody against phosphorylated tyrosine. The result shown is 
representative for three individual experiments. (c) Immunoprecipitation using a PLC2-specific 
antibody. Washed platelets from wild-type and Rac1-/- mice were stimulated as described under (a). 
Precipitates were blotted and stained using an antibody specific for phosphorylated tyrosine (upper 
panel) and an antibody against PLC2 (lower panel). The result shown is representative for three 
individual experiments. (d) Washed platelets were activated with 1 µg/ml PMA, stained with JON/A-PE 
and anti-P-selectin-FITC and directly analysed by flow cytometry. The results are expressed as MFI ± 
SD (n=6 per group). (Pleines I et al., Pflugers Arch 200980.) 
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The PLC2 activation defect was not based on reduced tyrosine phosphorylation of 
the enzyme in response to GPVI stimulation as shown by whole cell tyrosine 
phosphorylation experiments, where the CVX-induced changes were 
indistinguishable between control and Rac1-/- platelets, including strong 
phosphorylation of a protein that migrated at the known position of PLC2 (155 kDa) 
(Fig. 15b). This was further confirmed by immunoprecipitation experiments, which 
yielded comparable increases in tyrosine phosphorylation of PLC2 in control and 
mutant platelets (Fig. 15c). 
To also test a possible involvement of Rac1 in the GPVI signaling cascade 
downstream of PLC2 but independent of Ca2+ mobilization, PKC-dependent 
activation was assessed. For this, control and Rac1-/- platelets were stimulated with 
the DAG analog PMA. No differences in aggregation (not shown), integrin IIb3 
activation, or P-selectin exposure were found (Fig. 15d), suggesting that Rac1 is not 
required for PKC-mediated activation processes in platelets. 
 
3.1.5 Defective adhesion and aggregation of Rac1-/- platelets on collagen 
under flow 
To investigate the functional consequences of Rac1 deficiency under more 
physiological conditions, platelet adhesion and thrombus formation on a collagen-
coated surface under flow in a whole blood perfusion system was analyzed84. Under 
both high (1000 s-1) and low (150 s-1) shear conditions, wild-type platelets rapidly 
adhered to the collagen surface and recruited additional platelets from the blood 
stream resulting in the formation of stable three-dimensional aggregates (Fig. 16a, 
left, b). In sharp contrast, adhesion of Rac1-/- platelets was significantly reduced as 
compared to the control and the formation of stable three-dimensional thrombi was 
virtually abrogated. As a result, the surface area covered by platelets at the end of 
the perfusion period was markedly reduced for Rac1-/- blood as compared to wild-
type and consisted almost exclusively of a single platelet layer (Fig. 16 a, middle, b).  
These results demonstrated that Rac1 was essential for the formation of stable three-
dimensional platelet thrombi on collagen under flow conditions. This is in line with a 
recent study by McCarty et al. who made similar observations but attributed this 
defect mainly to the important function of Rac1 in the agonist-induced reorganization 
of the cytoskeleton leading to lamellipodia formation and spreading33. In contrast to 
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this hypothesis, the data shown here indicated that the defect in GPVI-induced 
activation and release of ADP and TXA2 could also be responsible for the inability to 
form three-dimensional thrombi. To discriminate between these two possibilities, it 
was next tested whether thrombus formation of Rac1-/- platelets could be restored by 
exogenously adding the ‘missing’ secondarily acting agonists. For this, ADP and 
U46619 were co-infused into Rac1-/- blood directly before it entered the flow 
chamber85. Under these experimental conditions, large thrombi formed within 2 min 
under high (Fig. 16a right, b) and low (not shown) shear conditions. These thrombi 
were stable and did not detach from the collagen-coated surface or shed emboli, 
demonstrating that Rac1-/- platelets can adhere and form shear-resistant thrombi on 
collagen when stimulated appropriately. These results suggest that the defect in 
GPVI-dependent cellular activation rather than the inability to form lamellipodia is the 
major cause for the markedly reduced thrombus stability observed with Rac1-/- 
platelets. This hypothesis is also in line with the observed unaltered morphology of 
Rac1-/- platelets activated in suspension (Fig. 10c). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 16. Impaired adhesion and defective thrombus formation of Rac1-/- platelets on collagen 
under flow. Whole heparinized blood of Rac1-/- and wild-type mice was perfused over a collagen 
coated cover slip for 4 min or 10 min at high (1000 s-1) or low (150 s-1) shear rates, respectively. 
Where indicated, 10 µM ADP and 1 µM U46619 were co-infused into the blood shortly before it 
entered the flow chamber. (a) Representative phase contrast images and (b) surface area covered by 
platelets (%) ± SD (n=6 per group) taken at the end of the perfusion time. (Pleines I et al., Pflugers 
Arch 200980.) 
 
 47
3  Results 
3.1.6 Defective arterial thrombus formation in Rac1-/- mice in vivo 
The above described experiments indicated that Rac1 deficiency results in a marked 
GPVI signaling defect and an inability of the platelets to spread on different 
substrates. To test the significance of this defect in arterial thrombus formation in 
vivo, two different well-established thrombosis models were used. In the first model, 
platelet adhesion at the injured carotid artery was analyzed by in vivo fluorescence 
microscopy (Fig. 17a,b). This model allows the visualization and quantification of 
platelet adhesion on the exposed subendothelial matrix which has been shown to be 
a largely GPVI-dependent process86. Platelets purified from donor mice of the same 
genotype were fluorescently labeled and injected into recipient mice. Vascular injury 
was induced by vigorous ligation of the carotid artery, a process that consistently 
causes disruption of the endothelial layer and frequent breaching of the internal 
elastic lamina, followed by rapid collagen-dependent platelet adhesion and aggregate 
formation. In wild-type mice, numerous platelets adhered to the site of injury within 
the first minutes after injury and virtually all platelets establishing an initial contact 
with the subendothelium remained firmly adherent (2,579 ± 218/mm2, t=5 min) (Fig. 
17a,b). In contrast, in Rac1-/- mice, the number of adherent platelets was reduced by 
57% as compared to control (1120.7 ± 74.6/mm2, t=5 min). An even more 
pronounced reduction in adhesion was observed in mice, in which GPVI had been 
depleted by treatment with the anti-GPVI antibody JAQ170 (362.7 ± 42/mm2, t=5 min), 
which served as a positive control. These results confirmed the importance of GPVI-
collagen interactions for platelet recruitment in this arterial injury model and revealed 
a central role of Rac1 in this process. 
The significance of Rac1 for arterial thrombus formation was demonstrated in a 
second model, where injury is mechanically induced in the aorta, and blood flow is 
monitored with an ultrasonic perivascular Doppler flow meter (Fig. 17c,d). After a 
transient increase directly after injury, blood flow progressively decreased for several 
minutes in all animals. In all wild-type mice (7/7), this decrease resulted in complete 
and irreversible occlusion of the vessel within maximally 7 min thereafter (mean 
occlusion time 3.0 ± 2.3 min. In sharp contrast, while a progressive reduction in blood 
flow was observed during the first minutes after injury in Rac1-/- mice, blood flow 
increased again to normal and 7 of 8 mice displayed essentially normal flow rates 
through the injured vessel at the end of the observation period (45 min). Similar 
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results were obtained with GPVI-depleted mice (not shown), confirming earlier 
results87.  
In agreement with the reduced thrombotic activity in Rac1-/- mice, these animals also 
exhibited prolonged bleeding times (Fig. 17e). Notably, bleeding times were highly 
variable suggesting thrombus instability as recently also described for mice lacking 
the 2A adrenergic receptor88. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 17. Rac1-/- platelets display a severe adhesion defect in vivo and do not form stable 
thrombi. (a) Platelet adhesion to the carotid artery 5 min after injury. CFSE-labeled platelets of the 
same genotype were injected into anesthetized wild-type, Rac1-/- and GPVI-depleted mice. The carotid 
artery was injured through ligation using a surgical filament and adhesion of platelets to the vessel wall 
was monitored over 10 min by fluorescence microscopy in vivo. (b) Statistical evaluation showing the 
adhesion of platelets to the vessel wall per mm2 ± SD of at least three independent experiments. (c) 
Aorta occlusion model. Representative graph of blood flow of a wild-type and Rac1-/- mouse after 
mechanical injury of the aorta [at t=0]. (d) Occlusion time after injury of the aorta. The aorta of all 
control mice occluded whereas in 7 out of 8 Rac1-/- mice blood flow did not stop during the 45 min 
observation period. (e) Tail bleeding times in wild-type and Rac1-/- mice. Each symbol represents one 
individual. (Pleines I et al., Pflugers Arch 200980.) 
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3.2 Cdc42-/- platelets display increased secretion but largely unaltered 
filopodia formation 
 
3.2.1 Cdc42-/- mice display mild thrombocytopenia 
Constitutive deletion of the Cdc42 gene results in embryonic lethality in mice48. To 
study the function of Cdc42 in platelets, mice carrying a Cdc42 gene flanked by loxP 
sites74 were crossed with transgenic mice expressing Cre recombinase under the 
control of the megakaryocyte- and platelet-specific platelet factor (PF) 4 promoter76. 
In resulting Cdc42 (fl/fl cre+) mice, gene deletion was induced intrinsically upon 
induction of the PF4 promoter during megakaryocyte maturation. Cdc42 (fl/fl cre-, 
further referred to as wild-type) mice derived from the same litters served as controls. 
The absence of Cdc42 protein in Cdc42 (fl/fl cre+, further referred to as Cdc42-/-) 
mice was confirmed by western blot analysis of platelet lysates using GPIIIa 
expression levels as loading control (Fig. 18a). Megakaryocyte- and platelet-specific 
deletion of Cdc42 resulted in a moderate thrombocytopenia with platelet counts 
ranging between 50 and 80% of control animals (Fig. 18b) indicating a role for Cdc42 
in megakaryocyte differentiation and/or the formation of platelets. Platelet size was 
only moderately but significantly increased in Cdc42-/- animals, as revealed by 
transmission electron microscopy (TEM) and determination of the platelet width (Fig. 
18c,d), as well as by flow cytometric assessment of the forward scatter (FSC) signal 
(Table 2). Expression of major platelet surface receptors was similar to controls with 
exception of subunits of the GPIb/V/IX complex, where expression levels were 
significantly decreased by approximately 20% in Cdc42-/- as compared to wild-type 
platelets (Table 2). 
 Table 2. Platelet glycoprotein ex-
pression in wild-type and Cdc42-/- 
mice. Expression of glycoproteins on 
the platelet surface was determined by 
flow cytometry. Diluted whole blood 
from the indicated mice was incubated 
with FITC-labeled antibodies at 
saturating concentrations for 15 min at 
RT and platelets were analyzed 
directly by flow cytometry. Results are 
expressed as mean fluorescence 
intensity  SD for 6 mice per group. 
Mean platelet size (mean FSC) was 
determined by FSC characteristics. 
(Pleines I et al., in press.) 
wild-type Cdc42-/-  
 345 ± 21 440 ± 37 mean FSC 
389 ± 8 306 ± 11 GPIb  
260 ± 4  212 ± 3  GPV  
403 ± 13 343 ± 2  GPIX  
1443 ± 21  1226 ± 10   CD9 
 61 ± 2 52 ± 3 GPVI 
 90 ± 4  90 ± 8  2 
 162 ± 10  183 ± 9  1  
IIb3 560 ± 63  513 ± 38   
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Figure 18. Cdc42-/- mice display mild thrombocytopenia. (a) Western blot analysis of Cdc42 
expression in wild-type Cdc42-/- platelets. GPIIIa expression was used as loading control. (b) 
Peripheral platelet counts (n=6 per group). (c) Representative transmission electron microscopy 
pictures from wild-type and Cdc42-/- platelets. Bar, 2 µm. (d) Mean platelet width of wild-type and 
Cdc42-/- platelets (n=25 per group). (Pleines I et al., Blood, in press.) 
 
3.2.2 Cdc42-/- platelets form filopodia and fully spread on fibrinogen 
Cdc42 has been demonstrated to be crucial for filopodia formation in various cell 
types, and also an essential role for filopodia formation in platelets has been 
reported32. To test this hypothesis directly, wild-type and Cdc42-/- platelets were 
allowed to spread on a fibrinogen-coated surface in the presence of thrombin (0.01 
U/ml final concentration, (Fig. 19). Surprisingly, Cdc42-/- platelets formed filopodia to 
a similar extent and with similar kinetics as wild-type platelets, and after 30 minutes 
the rate of fully spread platelets was comparable between the two groups (Fig. 19b). 
The filopodia formed in Cdc42-/- platelets (Fig. 19a, lower panel) were microscopically 
indistinguishable from those formed in wild-type platelets (Fig. 19a, upper panel). 
Likewise, Cdc42-/- and wild-type platelets exhibited similar morphology and filopodia 
structure upon adhesion on fibrinogen under either unstimulating conditions (Fig. 
19c) or upon activation with 5 M ADP (not shown). These data demonstrate that 
Cdc42 is not required for filopodia formation and spreading of platelets on a 
fibrinogen matrix.  
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Figure 19. Cdc42-/- platelets are able to form filopodia and to spread on fibrinogen. (a) Washed 
platelets from the indicated mice were allowed to adhere and spread on immobilized human fibrinogen 
(100 µg/ml) upon activation with thrombin (0.01 U/ml). DIC images were taken at the indicated time 
points (5, 15, 20 min), representative of 4 individual experiments. Bar, 5 µm. (b) Statistical analysis of 
the percentage of spread Cdc42-/- and wild-type platelets observed at different spreading stages at the 
indicated time points. 1: roundish, no filopodia, no lamellipodia. 2: only filopodia. 3: filopodia and 
lamellipodia. 4: full spreading; only lamellipodia. Bar, 5 µm. (c) Scanning electron microscopy (SEM) of 
wild-type and Cdc42-/- platelets upon adhesion on fibrinogen without agonist stimulation. Bar, 2.5 µm. 
(Pleines I et al., Blood, in press.) 
 
For a more detailed analysis of the cytoskeletal ultrastructure in Cdc42-deficient 
platelets, scanning electron microscopic studies were performed (Fig. 20). Apart from 
their increased size, no morphological differences between resting Cdc42-/- and wild-
type platelets were noted (Fig. 20a) and also thrombin-induced (30 min) filopodia 
were not different in length or shape between the two groups (Fig. 20b). To also 
study the impact of Cdc42 deficiency on platelet shape change in suspension, 
washed platelets were activated with ADP or thrombin under stirring conditions for 15 
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seconds and visualized by scanning electron microscopy (Fig. 20c). Under these 
conditions, Cdc42-/- and control platelets displayed a similar morphology including a 
contracted cell body and the formation of numerous filopodia (Fig. 20c, right panel).  
Taken together, these results reveal normal formation and structure of filopodia and 
normal spreading morphology, as well as normal agonist-induced shape change in 
Cdc42-/- platelets. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 20. Normal ultrastructure of Cdc42-/- platelets. (a–c) Scanning electron microscopy (SEM) of 
Cdc42-/- and wild-type platelets. (a) resting platelets immobilized on poly-L-lysine. Bar, 5 µm. (b) 
Spread Cdc42-/- and wild-type platelets upon activation with 0.01 U/ml thrombin on human fibrinogen 
(100 µg/ml). Upper panel: SEM of intact platelets. Lower panel: visualization of the actin cytoskeleton 
after denudation of the plasma membrane. Bar, 2 µm. (c) Morphology of Cdc42-/- and wild-type 
platelets in suspension at 15 seconds after activation with thrombin (0.01 U/ml, upper panel) or ADP 
(5 µM, lower panel). Bar, 1 µm. (Pleines I et al., Blood, in press.) 
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3.2.3 Cdc42-/- platelets exhibit reduced filopodia extension following adhesion 
on immobilized vWF 
In the next step, the platelet response upon adhesion to a mouse vWF coated 
surface under conditions of integrin IIb3 blockade was evaluated (Fig. 21a,b). 
Under these conditions, a GPIb-specific signal is triggered resulting in shape change 
that is limited to contraction of the cell body and filopodia formation89. In contrast to 
control platelets, which efficiently extended filopodia (75% showing more than 3 
filopodia), Cdc42-/- platelets exhibited a profound decrease in the ability to form 
filopodia with a majority displaying no (25%) or less than 4 (50%) filopodia per 
platelet and being unable to contract their cell body. Importantly, the observed defect 
in filopodia formation in Cdc42-/- platelets was not caused by decreased GPIb 
expression levels of the protein since GPIb-dependent agglutination by botrocetin 
and human vWF was unaltered in the mutant platelets as compared to controls (Fig. 
21c). Furthermore, filopodia formation upon static adhesion on collagen-related 
peptide (CRP), which acts via glycoprotein (GP) VI and has been proposed to induce 
similar signaling events as compared to GPIb, occurred to a similar extent in wild-
type and Cdc42-/- platelets (not shown). Together, these results suggest a specific 
role of Cdc42 in filopodia formation downstream of GPIb in a signaling pathway 
differing from that triggered by GPVI or G protein-coupled receptors. 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 21. Cdc42-/- platelets exhibit reduced filopodia extension on vWF. (a) Washed platelets 
were treated with Integrilin (40 µg/ml) and botrocetin (2 µg/ml) and allowed to adhere to coverslips 
coated with 10 µg/ml of mouse von Willebrand factor (vWF) for 20 min at 37°C. Samples were fixed 
with 2.5 % glutaraldehyde and processed for SEM. Images are representative of 5 experiments (Bar, 
2.5 µm). (b) Filopodia formation was scored according to the number of extensions per platelet (0, 1 to 
3, >3) in five different fields corresponding to a total surface of 9215 µm2. The results are mean values 
± SD (n=5 per group). (c) Unaltered agglutination of Cdc42-/- platelets. Washed Cdc42-/- and wild-type 
platelets were stimulated with botrocetin (5 µg/ml) and human vWF (10 µg/ml) in presence of 40 µg/ml 
Integrilin under stirring conditions and agglutination was monitored over 15 min using an 
aggregometer. Curves are representative of 3 individual experiments. (Pleines I et al., Blood, in 
press.) 
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3.2.4 Increased secretion in Cdc42-/- platelets 
Cdc42 has been demonstrated to be required for exocytotic processes in various cell 
types, such as mast cells, where it was shown to be crucially involved in antigen-
stimulated secretion65;66. To address a possible role of Cdc42 in this process in 
platelets, the ability of Cdc42-/- and wild-type platelets to release granules upon 
agonist activation was determined by flow cytometry (Fig. 22b). In parallel, activation 
of the main platelet integrin, IIb3, was assessed (Fig. 22a). Surprisingly, and in 
contrast to studies in other cell types, it was found that P-selectin expression was not 
decreased but markedly increased in Cdc42-/- as compared to wild-type platelets in 
response to all tested strong agonists (Fig. 22b). In contrast, integrin IIb3 
activation in response to strong stimuli was moderately decreased in Cdc42-/- 
platelets compared to wild-type controls (Fig. 22a).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 22. Increased P-selectin expression in Cdc42-/- platelets upon activation. Flow cytometric 
analysis of (a) IIb3 integrin activation (binding of JON/A-PE, upper panel) and (b) degranulation-
dependent P-selectin exposure (lower panel) in response to the indicated agonists from control (black) 
or Cdc42-/- (gray) platelets. Abbreviation: U46: U46619. Results are mean fluorescent intensities (MFI) 
± SD of 6 mice per group. (Pleines I et al., Blood, in press.) 
 
The increased levels of P-selectin expression in Cdc42-/- platelets indicated 
enhanced release of  granules. To test whether release of dense granules was also 
affected, the amount of released ATP and serotonin upon agonist stimulation were 
measured (Fig. 23). Strongly increased ATP release in Cdc42-/- compared to wild-
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type platelets was found in response to thrombin and CRP (Fig. 23a), whereas 
serotonin release was not significantly different compared to the control (Fig. 23b).  
 
 
 
 
 
 
 
 
 
 
 
Figure 23. Increased ATP release in Cdc42-/- platelets upon activation. Measurement of (a) 
released ATP and (b) serotonin in the supernatant of resting or activated wild-type (black) and Cdc42-/- 
(gray) platelets. Results are given as mean ATP concentration (M) and mean serotonin concentration 
(ng/3.2x106 platelets) ± SD (n=4 per group). (Pleines I et al., Blood, in press.) 
 
Transmission electron microscopy revealed comparable numbers of  and dense 
granules in Cdc42-/- and control platelets (not shown) and no significant differences 
between wild-type and mutant cells were found in the total amount of the 
representative -granular proteins P-selectin and vWF (Fig. 24a,b). Thus, together 
with the results from flow cytometry, these data support the hypothesis of increased 
 granule-dependent secretion in Cdc42-/- platelets. 
In contrast, the content of dense granule-specific ADP and ATP was significantly 
increased in resting Cdc42-/- platelets (Fig. 24c), whereas levels of serotonin were not 
significantly altered (Fig. 24d). The observed increased ADP/ATP content may to a 
certain extent be related to the increased size of Cdc42-/- platelets compared to the 
control. Additionally, alterations in the process of granule packing may also contribute 
to the observed enhanced secretion from dense granules in Cdc42-/- platelets.  
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Figure 24. Partial changes in the granule content of Cdc42-/- platelets. (a,b) No significant 
changes in platelet -granular P-selectin (a) and vWF content (b) in wild-type (black) and Cdc42-/- 
(white) platelets. Results are expressed as mean OD450/0.05x106 platelets and OD450/0.04x106 
platelets ± SD of 4 mice per group. (c) Increased nucleotide content in Cdc42-/- platelets. 
Determination of ADP (left) and ATP (right) content in wild-type (white) and Cdc42-/- (black) platelets 
by HPLC. Results are expressed as nmol/108 platelets ± SD of 6 mice per group. (d) Unaltered 
serotonin content in Cdc42-/- platelets. Results are expressed as ng/3.2x106 platelets ± SD of 4 mice 
per group. (Pleines I et al., Blood, in press.) 
 
3.2.5 Enhanced aggregation of Cdc42-/- platelets at low agonist concentrations  
To study the functional consequences of the increased granule content and secretion 
and slightly decreased IIb3 integrin activation in Cdc42-/- platelets, aggregation 
studies were performed (Fig. 25). In this assay, the amount of released secondary 
mediators from platelet granules has a high impact on the aggregation response 
because of the high platelet concentrations in the suspension. Whereas the overall 
maximal aggregatory response to all tested agonists was similar in Cdc42-/- and wild-
type platelets (Fig. 25a-c), strongly enhanced aggregation of Cdc42-/- platelets was 
seen at threshold concentrations of the thromboxane (TXA2) analog U46619, CRP 
and collagen (Fig. 25b,c). The degree of aggregation in response to these agonists is 
known to be strongly dependent on released secondary mediators indicating that the 
increased secretion of Cdc42-/- platelets accounted for this effect. Consistent with 
this, aggregation in response to the weak agonist ADP, which alone does not induce 
degranulation, was similar in Cdc42-/- and wild-type platelets (Fig. 25a,c). No 
significant difference in aggregation between wild-type and mutant platelets could be 
detected in reponse to thrombin (Fig. 25a,c). Notably, Cdc42-/- platelets did not 
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aggregate spontaneously upon addition of epinephrine (not shown) indicating that the 
mutant platelets were not per se in a pre-activated state under the in vitro conditions 
used here.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 25. Enhanced aggregation of Cdc42-/- platelets at low agonist concentrations. Washed 
platelets from wild-type (black) or Cdc42-/- (gray) mice were stimulated with the indicated agonists and 
light transmission was recorded on a Fibrintimer 4 channel aggregometer. ADP measurements were 
performed using platelet-rich plasma. The results are representative of 3 individual experiments. (a,b) 
representative aggregation curves. (c) Bar graphs of results obtained by aggregometry. Results are 
given as the mean % of aggregation ± SD. (Pleines I et al., Blood, in press.) 
 
3.2.6 Cdc42-/- platelets form aggregates of increased size on collagen under 
flow  
At sites of vessel wall injury, release of secondary mediators from activated platelets 
at the exposed subendothelium plays a crucial role for the recruitment and activation 
of further platelets to promote thrombus formation. To study the effect of enhanced 
secretion of Cdc42-/- platelets on aggregate formation under flow, anti-coagulated 
whole blood was perfused over a collagen-coated surface at a shear rate of 1000 s-1 
(Fig. 26). A moderate but significant increase in aggregate size of Cdc42-/- platelets 
compared to wild-type platelets was observed under these conditions (Fig. 26, right 
panel), whereas the surface coverage was comparable between the two groups (Fig. 
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26, left panel). Thus, the increased release of granule contents in Cdc42-/- platelets 
translated into moderately increased aggregate formation under flow.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 26. Cdc42-/- platelets form stable aggregates on collagen under flow. Whole blood from 
wild-type or Cdc42-/- mice was perfused over a collagen-coated surface (0.2 mg/ml). (a,b) Increased 
aggregate formation of Cdc42-/- platelets at high (1000 s-1) shear rates. (a) Representative phase 
contrast (upper panel) and fluorescence images (lower panel) of aggregate formation on collagen after 
4 min perfusion time. Bar, 100 µm. (b) Mean surface coverage (left) and relative thrombus volume 
expressed as integrated fluorescence intensity (IFI) per mm2 (right) ± SD of 6 mice per group. (Pleines 
I et al., Blood, in press.) 
 
3.2.7 Cdc42-/- platelets display a decreased life span in vivo 
Non-functional or pre-activated platelets are thought to be rapidly cleared from the 
circulation by the reticulo-endothelial system which may, if occurring constantly, lead 
to thrombocytopenia. Since Cdc42-/- platelets displayed mild thrombocytopenia, the 
platelet life span in Cdc42-/- and wild-type mice in vivo was determined (Fig. 27). For 
this, circulating platelets were labeled with a fluorescently labeled non-cytotoxic 
antibody derivative and the labeled platelet population was monitored over time. After 
1 hour (day 0), >90% of the circulating platelets in control and Cdc42-/- mice were 
labeled and this platelet population gradually decreased over 5 days in wild-type 
mice, which is in agreement with the approximate 5 day life span of mouse platelets.  
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Figure 27. Cdc42-/- platelets display a decreased life span. Determination of the percentage of 
fluorescently labeled platelets of wild-type (black) and Cdc42-/- platelets (gray) for 5 days upon 
injection with 0.5 µg/g bodyweight anti-GPIX-Dylight 488 derivative on day 0. (Pleines I et al., Blood, in 
press.) 
 
In marked contrast, a dramatically shortened life span was seen in Cdc42-/- mice, 
with a decrease to 39.8 ± 7.6% and 0% on days 1 and 3, respectively. This result 
clearly demonstrates that, Cdc42 deficiency has only moderate effects on platelet 
function ex vivo, it significantly affects their homeostatic function in vivo resulting in a 
markedly increased turnover which may, at least in part, account for the moderate 
thrombocytopenia seen in these animals.  
 
3.2.8 Prolonged bleeding times in Cdc42-/- mice 
To study the effect of Cdc42 deficiency on hemostasis, tail bleeding experiments 
were performed (Figure 28). Very unexpectedly, a significant hemostatic defect was 
detectable in Cdc42-/- mice. Whereas bleeding stopped in all control mice within 10 
minutes (mean: 5.9 ± 2.2 min), bleeding times were highly variable and generally 
increased in Cdc42-deficient animals (mean: 13.5 ± 5.3 min). However, all tested 
animals were able to stop bleeding within the observation period of 20 minutes. 
 
 
 
 
 
 
 
 
 
 
 
Figure 28. Prolonged bleeding in Cdc42-/- mice. Increased tail bleeding times in Cdc42-/- mice (gray) 
compared to wild-type (black) mice. Each symbol represents one individual. (Pleines I et al., Blood, in 
press.) 
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3.2.9 Accelerated occlusive arterial thrombus formation in Cdc42-/- mice 
To investigate the effect of Cdc42 deficiency on thrombus formation in vivo, platelet 
accumulation at sites of ferric chloride induced mesenteric arteriole injury was 
monitored using intravital fluorescence microscopy (Fig. 29). Remarkably, although 
the beginning of thrombus formation followed similar kinetics in control and Cdc42-
deficient mice (Fig. 29a), the interval between the formation of first thrombi and 
complete occlusion of the respective arteriole was significantly shorter in Cdc42-
deficient animals (Fig. 29b) as compared to wild-type controls. Within 6 minutes after 
appearance of the first thrombus >10 µm, vessel occlusion occurred in 60% of the 
Cdc42-deficient animals (9/15), whereas no vessel occlusion was observed in 
arterioles of control mice during this time period. These results indicate that in this 
model of vessel wall injury, the increased secretion of Cdc42-/- platelets plays a 
significant role in occlusive thrombus formation.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 29. Accelerated thrombus formation in Cdc42-/- mice. (a–c) Mesenteric arterioles were 
injured with FeCl3 and adhesion and thrombus formation of fluorescently-labeled platelets was 
monitored in vivo by fluorescence microscopy. (a) Time to appearance of first thrombus and (b) 
interval between start of thrombus formation and vessel occlusion are shown. Each symbol represents 
one individual. (c) Representative images are depicted. Bar, 50 µm. The asterisk indicates occlusion 
of the vessel. (Pleines I et al., Blood, in press.) 
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3.2.10  Increased amounts of phosphorylated cofilin in Cdc42-/- platelets 
To test a possible effect of Cdc42 deficiency on agonist-induced cytoskeletal 
rearrangements, the Cdc42 downstream effector cofilin was examined, which is a 
protein known to be involved in increasing actin turnover in its active 
dephosphorylated form90. Unexpectedly, and in contrast to the currently proposed 
function of Cdc4229 (see Fig. 7), not a decrease, but a strong (approximately 3-fold) 
increase in the (inactive) phosphorylated cofilin form was found in resting Cdc42-/- 
platelets as compared to controls (Fig. 30a,b). This finding is in accordance with a 
recent study showing increased cofilin phosphorylation in cortical neurons upon 
genetic Cdc42 deletion91. Thrombin-induced dephosphorylation of cofilin occurred to 
a similar extent and with similar kinetics in wild-type and Cdc42-/- platelets, although 
higher levels of the inactive, phosphorylated form of the protein were consistently 
detected in the mutant cells under all experimental conditions (Fig. 30c).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 30. Increased phosphorylation of cofilin in Cdc42-/- platelets. (a) Western blots of lysates 
from unstimulated wild-type (black) and Cdc42-/- (gray) platelets using antibodies against the 
phosphorylated form of cofilin, cofilin and GPIIIa (loading control). (b) Densitometric analysis of relative 
expression levels of phospho-cofilin (left) and total cofilin (right) in unstimulated wild-type (black) and 
Cdc42-/- (gray) platelets. (c) Washed platelets from wild-type (left) and Cdc42-/- mice were stimulated 
with 0.1 U/ml thrombin and lysed at the indicated time points. Lysates were blotted and membranes 
were probes using antibodies against phospho-cofilin, cofilin and GPIIIa (loading control). (Pleines I et 
al., Blood, in press.) 
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3.3 Double deficiency of Rac1 and Cdc42 severely affects platelet function 
and production 
As described in Fig. 7, Rac1 and Cdc42 have been reported to share similar 
downstream signaling pathways and in platelets p21-activated kinase (PAK) has 
been shown to become activated by both GTPases92. Therefore, Rac1 and Cdc42 
may have redundant functions in megakaryocytes and platelets. To address this 
question in detail by a knock-out approach, Rac1/Cdc42 (fl/fl) mice were generated 
by intercrossing. These mice were then crossed with either PF4-Cre or Mx-Cre 
transgenic mice to receive Rac1/Cdc42 (fl/fl cre+) mice.  
In case of the PF4-Cre system, gene deletion occurred intrinsically during 
megakaryocyte maturation (see section 3.2.1). For generation of a hematopoietic 
Rac1/Cdc42 knock-out, the Mx-Cre system was used to induce gene deletion in adult 
mice as described (see section 3.1.1). For both systems, Rac1/Cdc42 (fl/fl cre-, 
further referred to as wild-type) mice derived from the same litters served as controls. 
The absence of Rac1 and Cdc42 in the respective Rac1/Cdc42 (fl/fl cre+, further 
referred to as Rac1/Cdc42-/-) mice was confirmed by western blot of platelet lysates 
as described (Fig. 31, see section 3.1.1).  
Comparison between the two different Cre systems revealed that, while the PF4-Cre-
induced knock-out was specific for megakaryocytes/platelets, the knock-out 
efficiency was slightly higher in the Mx-Cre system. However, due to its unspecifity, 
the Mx-Cre-induced double knock-out lead to death of the animals between 9 and 14 
days after Cre induction. In contrast, Rac1/Cdc42-/- mice generated using the PF4-
Cre system were viable and fertile and did not show any signs of disease (not 
shown). Therefore, in the following studies, Mx-Cre-induced gene deletion was 
mainly used for platelet studies, whereas studies on megakaryocytes were performed 
using the PF4-Cre system. 
 
 
 
Figure 31. Absence of Rac1 and Cdc42 protein in 
Rac/Cdc42-/- platelets. Western blot analysis of 
Rac1 and Cdc42 expression in wild-type and 
Rac1/Cdc42-/- platelets generated by the Mx-Cre/loxP 
system. GPIIIa expression was used as loading 
control.  
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3.3.1 Study of Rac1/Cdc42-/- platelets 
3.3.1.1 Rac1/Cdc42 double deficiency leads to macrothrombocytopenia and 
formation of abnormal platelets 
Interestingly, whereas Rac1-/- mice displayed no and Cdc42-/- mice only a moderate 
decrease in platelet counts, double deficiency of Rac1 and Cdc42 resulted in severe 
thrombocytopenia with platelet counts below 10% of control mice (Fig. 32b). In 
contrast, the size of Rac1/Cdc42-/- platelets was dramatically increased, as 
demonstrated by transmission electron microscopy (TEM) and determination of the 
mean platelet volume (Fig. 32a,c). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 32. Rac1/Cdc42-/- mice display severe macrothrombocytopenia. (a) Representative 
transmission electron microscopy pictures from wild-type and Rac1/Cdc42-/- platelets. Bar, 2 µm. (b,c) 
Comparison of peripheral platelet counts (b) and mean platelet volume (c) of wild-type, Rac1-/-, Cdc42-
/- and Rac/Cdc42-/- platelets (n=15 per group). Results are expressed as platelets/µl and fl  SD, 
respectively. 
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Detailed analysis of platelet ultrastructure by TEM revealed dramatically altered 
ultrastructure in Rac1/Cdc42-/- platelets (Fig. 33). Whereas Rac1-/- and Cdc42-/- 
platelets displayed unaltered granule number and content as compared to wild-type 
platelets (Fig. 33a), platelets from Rac1/Cdc42-/- mice were partially overloaded with 
granules and/or vacuoles while others were found to be completely empty (Fig. 33b). 
Furthermore, expression levels of prominent platelet surface receptors were 
markedly reduced in Rac1/Cdc42-/- platelets with exception of integrin expression 
which was similar to controls (Table 3). 
Taken together, these results demonstrated a critical and potentially redundant 
function of Rac1 and Cdc42 in the processes of megakaryocyte maturation and/or 
platelet production. 
 
 
 
d
 
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Figure 33. Rac1/Cdc42-/- platelets show abnormal ultrastructure. Representative transmission 
electron microscopy pictures are depicted. (a) Normal ultrastructure of wild-type, Rac1-/- and Cdc42-/- 
platelets. Bar, 1 µm. (b) Abnormal ultrastructure of Rac1/Cdc42-/- platelets. Bar sizes are depicted. 
Abbreviations: ,  granule; d, dense granule; v, vacuole. 
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 wild-type Rac1/ 
Cdc42-/- 
GPIb 452 ± 7 270 ± 23 
GPV 386 ± 5  252 ± 24  
GPIX 615 ± 9 416 ± 20  
CD9 1210 ± 35  1113 ± 140 
GPVI 44 ± 3  29 ± 1  
2 112 ± 7  107 ± 5  
1 149 ± 10  165 ± 8  
IIb3 813 ± 42  732 ± 27 
 
Table 3. Platelet glycoprotein expression in wild-type and Rac1/Cdc42-/- mice. Expression of 
glycoproteins on the platelet surface was determined by flow cytometry. Diluted whole blood from the 
indicated mice was incubated with FITC-labeled antibodies at saturating concentrations for 15 min at 
RT and platelets were analyzed directly. Results are expressed as mean fluorescence intensity  SD 
for 5 mice per group. 
 
3.3.1.2 Rac1/Cdc42-/- platelets are unable to spread on fibrinogen upon 
activation 
To test the ability of the Rac1/Cdc42-/- platelets to undergo shape change and to 
rearrange the actin cytoskeleton, spreading experiments on fibrinogen (100 µg/ml) 
upon thrombin (0.01 U/ml) stimulation were performed. As already shown in sections 
3.2.2 and 3.1.2, Cdc42-/- platelets spread normally under these conditions, whereas 
Rac1-/- platelets were unable to form lamellipodia. Rac1/Cdc42-/- platelets were still 
able to tightly adhere to the fibrinogen matrix and, as expected from Rac1 deficiency, 
double-deficient platelets were unable to form lamellipodia. Most adherent 
Rac1/Cdc42-/- platelets contracted and partially exceeded long filopodia but 
spreading was completely abolished (Fig. 34a,b).  
To determine whether the spreading defect of the double-mutant platelets was 
caused by defective actin assembly, F-actin contents in resting and thrombin-
stimulated (1 U/ml) wild-type, Rac1-/-, Cdc42-/- and Rac1/Cdc42-/- platelets were 
measured by flow cytometry. Interestingly, the increase in F-actin content upon 
thrombin stimulation was similar in all tested mouse lines, indicating that actin 
assembly could still take place in absence of Rac1 and Cdc42 (Fig. 34c). This result 
suggested that defective spreading in the double-deficient mice was caused by 
inhibited actin reorganization rather than by a general defect in F-actin assembly. 
 66
3  Results 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 34. Defective spreading of Rac1/Cdc42-/- platelets on fibrinogen. (a) Washed platelets from 
the indicated mice were allowed to adhere and spread on immobilized human fibrinogen (100 µg/ml) 
upon activation with thrombin (0.01 U/ml). DIC images were taken at the indicated time points (5, 15, 
30 min), representative of 4 individual experiments. Bar, 5 µm. (b) Statistical analysis of the 
percentage of spread Rac1/Cdc42-/- and wild-type platelets observed at different spreading stages at 
the indicated time points. 1: roundish, no filopodia, no lamellipodia. 2: only filopodia. 3: filopodia and 
lamellipodia. 4: full spreading; only lamellipodia. (c) Determination of relative F-actin contents ± SD in 
resting and thrombin-activated (1 U/ml) wild-type, Rac1-/-, Cdc42-/- and Rac1/Cdc42-/- platelets. 
 
Detailed analysis of Rac1/Cdc42-/- platelets by SEM confirmed the increased size of 
the cells (Fig. 35a) and revealed that spread (30 min, 0.01 U/ml thrombin) 
Rac1/Cdc42-/- platelets were less contracted than Rac1-/- platelets (see section 3.1.2) 
(Fig. 35b, upper and middle panel). In addition, filopodia exhibited by the mutant 
platelets were thinner than those formed by Rac1-/- platelets. Visualization of the 
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cytoskeleton by denudation of the plasma membrane demonstrated defective actin 
reorganization upon activation in spread Rac1/Cdc42-/- platelets (Fig. 35b, lower 
panel).  
Taken together, these results showed that lack of Rac1 and Cdc42 resulted in 
abrogated spreading and actin rearrangement defects in double-mutant platelets. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 35. Scanning electron microscopical analysis of Rac1/Cdc42-/- platelets. (a) Increased 
size of resting Rac1/Cdc42-/- platelets immobilized on poly-L-lysine. Bar, 5 µm. (b) Visualization of 
defective actin reorganization and spreading of Rac1/Cdc42-/- platelets on fibrinogen (100 µg/ml) upon 
activation with 0.01 U/ml thrombin (time point: 30 min). Upper panel: Overview (bar, 5 µm). Middle and 
lower panel: Detail of spread wild-type and Rac1/Cdc42-/- platelets. Middle panel: SEM of intact 
platelets. Bar, 2 µm. Lower panel: visualization of the actin cytoskeleton after denudation of the 
plasma membrane. Bar, 2 µm.  
 
3.3.1.3 Defective integrin activation and degranulation in Rac1/Cdc42-/- 
platelets 
The results from electron microscopy and spreading studies indicated platelet 
function defects upon Rac1/Cdc42 double deficiency. To investigate whether 
Rac1/Cdc42-/- platelets were activatable and release granules, integrin IIb3 
activation and  granule-dependent P-selectin exposure upon platelet activation with 
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different agonists was determined by flow cytometry (Fig. 36). Whereas Rac1-/- 
platelets showed a selective ITAM activation defect and P-selectin expression was 
enhanced in Cdc42-/- platelets (see sections 3.1.3 and 3.2.4) Rac1/Cdc42-/- platelets 
displayed markedly decreased integrin activation (Fig. 36a) and P-selectin 
expression (Fig. 36b) in response to all tested stimuli, including ITAM- as well as G-
protein-coupled agonists. 
Thus, double deficiency of Rac1 and Cdc42 resulted in severe activation and 
degranulation defects in platelets which were not restricted to specific signaling 
pathways. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 36. Decreased integrin activation and granule release in Rac1/Cdc42-/- platelets upon 
activation. Flow cytometric analysis of (a) IIb3 integrin activation (binding of JON/A-PE) and (b) 
degranulation-dependent P-selectin exposure in response to the indicated agonists from control 
(black) or Rac1/Cdc42-/- (patterned) platelets. Results are mean fluorescent intensities (MFI) ± SD of 5 
mice per group. 
 
3.3.1.4 Rac1/Cdc42-/- platelets are rapidly cleared from the circulation  
Non-functional or pre-activated platelets are constantly cleared from the circulation 
by the reticulo-endothelial compartment, in order to prevent spontaneous aggregation 
in the vascular system. To address the question whether constant removal of 
platelets from the circulation contributed to the macrothrombocytopenia observed in 
 69
3  Results 
Rac1/Cdc42-/- mice, the platelet life span was determined as described in section 
3.2.7. One hour after injection of a platelet-specific fluorescently labeled antibody 
derivative in vivo, 90% of wild-type, as well as Rac1/Cdc42-/- platelets were labeled 
(Fig. 37a). In wild-type mice the percentage of labeled platelets gradually decreased 
down to 0% on day 5. In contrast, in Rac1/Cdc42-/- mice, the population of 
fluorescent platelets was less then 10% already on day 2 and 0% on day 3. However, 
a per-se pre-activation of the double-deficient platelets was probably not the major 
cause of the decreased platelet life span, since flow cytometric measurements 
revealed that the weak agonist epinephrine was not able to induce integrin activation 
or degranulation in Rac1/Cdc42-/- platelets in vitro (Fig. 37b). Thus, the rapid 
clearance of Rac1/Cdc42-/- platelets was probably rather caused by intrinsic defects 
which is in line with the markedly altered ultrastructure observed by TEM (Fig. 33). 
Taken together, these results showed that defects in production of functional 
Rac1/Cdc42-/- platelets resulted in a dramatically decreased platelet span in vivo 
which may contribute to the macrothrombocytopenia observed in the double-deficient 
animals. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 37. Decreased platelet life span in Rac1/Cdc42-/- mice. (a) Decreased life span of 
Rac1/Cdc42-/- platelets. Determination of the percentage of fluorescently labeled platelets of wild-type 
(black) and Rac1/Cdc42-/- platelets (patterned) for 5 days upon injection with 0.5 µg/g bodyweight 
GPIX-Dylight 488 derivate on day 0. (b) Rac1/Cdc42-/- platelets are not per se pre-activated under in 
vitro conditions. Flow cytometric analysis of IIb3 integrin activation (binding of JON/A-PE, upper 
panel) and degranulation-dependent P-selectin exposure (lower panel) in resting and epinephrine-
stimulated (10 µM) wild-type (black), Rac1-/- (dark gray), Cdc42-/- (light gray) and Rac1/Cdc42-/- 
(patterned) platelets. Results are mean fluorescence intensities (MFI) ± SD of 4 mice per group. 
 
 
 70
3  Results 
3.3.1.5 Rac1/Cdc42-/- mice display defective hemostasis and defective 
thrombus formation in vivo 
The results presented above demonstrated marked defects in the formation of 
functional platelets in Rac1/Cdc42-/- mice. To investigate the relevance of GTPase 
double deficiency for hemostasis in vivo, tail bleeding times in wild-type and 
Rac1/Cdc42-/- mice were determined (Fig. 38a). Whereas bleeding in wild-type 
animals stopped within 7 minutes, none of the double-deficient animals was able to 
arrest bleeding within the observation time of 20 minutes. Thus, while single 
deficiency in either Rac1 or Cdc42 resulted in variable bleeding times, lack of both 
GTPases lead to a severe hemostatic defect in mice.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 38. Defective hemostasis and thrombus formation in Rac1/Cdc42-/- mice. (a) Infinite tail 
bleeding in Rac1/Cdc42-/- mice (patterned) compared to wild-type (black) mice. Each symbol 
represents one individual. (b–d) Mesenteric arterioles were injured with 20% FeCl3 and adhesion and 
thrombus formation of fluorescently-labeled platelets was monitored in vivo by fluorescence 
microscopy. Time to appearance of first thrombi (b) and occlusion times (c) are shown. Each symbol 
represents one individual. (d) Representative images are depicted. Bar, 50 µm. The asterisk indicates 
occlusion of the vessel. 
 
Recent studies in mice using intravital microscopy revealed that three-dimensional 
thrombi can still be formed under conditions of decreased platelet counts. To test the 
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impact of GTPase double deficiency on arterial thrombus formation Rac1/Cdc42-/- 
mice were challenged in an in vivo model in which oxidative injury of mesenteric 
arterioles is induced by application of ferric chloride (Fig. 38b-d). Under these 
conditions, wild-type, as well as Rac1-/- (not shown) and Cdc42-/- mice (see section 
3.2.9) were able to form stable thrombi which occluded the injured vessels. In 
contrast, beginning of thrombus formation was only observed in 50% of Rac1/Cdc42-
/- mice (Fig. 38b) and the formation of three-dimensional aggregates was completely 
abolished. Thus, no vessel occlusion was observed in the double-deficient mice 
during the observation time of 50 minutes (Fig. 38c,d). 
Taken together, these results demonstrated defective hemostasis and thrombus 
formation in Rac1/Cdc42-/- mice. 
 
 
3.3.2 Megakaryocyte studies 
3.3.2.1 Megakaryocytes are present in spleen and bone marrow of Cdc42-/- and 
Rac1/Cdc42-/- mice 
Intact megakaryocyte differentiation and maturation is critical for the formation of 
functional platelets. The results of the platelet studies had revealed mild 
thrombocytopenia in Cdc42-/- and severe macrothrombocytopenia in Rac1/Cdc42-/- 
mice. This thrombocytopenia might at least partially be caused by the constant 
removal of pre-activated and/or non-functional platelets as indicated by the 
decreased platelet life span observed in these mice. Alternatively, defects in 
megakaryocyte formation and/or platelet production might account for the decreased 
platelet counts. To compensate the low number of circulating platelets, 
thrombocytopenia is often associated with increased megakaryocyte production. 
To address this issue, the number of megakaryocytes in spleen and bone marrow 
sections derived from wild-type, Rac1-/-, Cdc42-/- and Rac1/Cdc42-/- mice was 
determined (Fig. 39). As expected from the normal platelet counts, Rac1-/- mice 
displayed unaltered MK numbers as compared to wild-type mice in spleen and bone 
marrow.  
In contrast, the number of MKs was highly increased in spleens of Cdc42-/- and 
Rac1/Cdc42-/- mice (Fig. 39a). In bone marrow, MK numbers were markedly 
increased in Cdc42-/- mice whereas no alteration was detectable for Rac1/Cdc42-/- 
mice as compared to wild-type animals (Fig. 39b). However, it is important to note 
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that the double-deficient MKs were difficult to observe in the sections due to their 
decreased demarcation towards surrounding cells, and therefore numbers may have 
been underestimated. Nevertheless, these results clearly demonstrated that MKs 
were present in Cdc42-/- and Rac1/Cdc42-/- mice, excluding a general defect in MK 
production as the reason for the thrombocytopenia in the animals. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 39. Megakaryocytes are present in spleen and bone marrow of Cdc42-/- and Rac1/Cdc42-/- 
mice. (a,b) Determination of MK numbers in hematoxylin-eosin-stained (a) spleen or (b) bone marrow 
sections from wild-type, Rac1-/-, Cdc42-/- and Rac1/Cdc42-/- mice. Left: Representative images. Black 
arrows indicate MKs. Right: Statistical analyis of MK numbers. Results are expressed as mean MK 
number per visual field  SD of 5 mice per group.  
 
3.3.2.2 Proplatelet formation is decreased in Cdc42-/- MKs and nearly 
abrogated in Rac1/Cdc42-/- MKs 
The presence of MKs in Cdc42-/- and Rac1/Cdc42-/- mice indicated that a defect in 
platelet production might account for the thrombocytopenia in the animals. Therefore, 
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in the next step, the ability of MKs derived from wild-type, Rac1-/-, Cdc42-/- and 
Rac1/Cdc42-/- mice to form proplatelets was determined. For this purpose, MKs 
isolated from adult bone marrow or fetal liver (E 14.5) were cultured in the presence 
of TPO to induce maturation and proplatelet formation in vitro (Fig. 40). Under these 
conditions, bone marrow- as well as fetal liver cell-derived Rac1-/- MKs were able to 
form proplatelets to a similar extent as wild-type platelets (Fig. 40a,b). In Cdc42-/- 
MKs, proplatelet formation was moderately but significantly reduced, indicating that, 
in case of single deficiency, Cdc42 might be of more importance for platelet 
production than Rac1. In marked contrast, proplatelet formation was strongly reduced 
in fetal liver cell-derived MKs (Fig. 40b) and nearly abrogated in bone marrow-
derived MKs (Fig. 40a) from Rac1/Cdc42-/- mice.  
Thus, these results point to a redundant role of Rac1 and Cdc42 in the processes of 
proplatelet formation and platelet production from MKs. 
 
 
 
 
 
 
 
Figure 40. Decreased proplatelet formation from MKs derived from Cdc42-/- and Rac1/Cdc42-/- 
mice. (a,b) Determination of proplatelet formation from cultured MKs derived from wild-type, Rac1-/-, 
Cdc42-/- and Rac1/Cdc42-/- mice. Results are expressed as % of proplatelet-forming MKs per visual 
field  SD from at least 5 samples per group. (a) Results from bone marrow-derived MKs (day 6 of 
culture). (b) Results from fetal liver-derived MKs (E 14.5, day 4 of culture). 
 
3.3.2.3 Intact endomitosis in MKs derived from Rac1-/-, Cdc42-/- and 
Rac1/Cdc42-/- mice 
Endomitosis represents a crucial process during MK maturation, leading to a DNA 
content up to 64N (see section 1.3). To determine whether PF4-Cre-induced lack of 
Rac1 and/or Cdc42 influenced endomitotic processes in MKs, the ploidy of bone 
marrow- and fetal liver-derived MKs was determined by flow cytometry (Fig. 41). For 
this purpose, MKs from whole bone marrow of adult mice or from fetal liver cell 
cultures (day 3 of culture) were stained with a fluorescently-labeled anti-integrin IIb 
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(GPIIb) antibody specific for MKs and platelets, as well as with propidium iodide (PI) 
for determination of the different DNA ploidy stages (Fig 41a). Under both conditions, 
the mean ploidy (counted from 8N) was similar in Rac1-/-, Cdc42-/- and Rac1/Cdc42-/- 
MKs as compared to wild-type MKs (Fig. 41a-c). Until now, it is not clearly defined at 
which stage of MK differentiation the PF4-Cre-mediated gene deletion is induced. 
However, it is assumed that gene deletion induced by this system occurs only after 
termination of the endomitotic stage during MK maturation, thereby not affecting 
endomitosis (see Fig. 3). Alternatively, endomitosis may still take place in Rac1 
and/or Cdc42-deficient MKs.   
 
 
 
 
 
 
 
 
 
 
 
 
Figure 41. Normal endomitosis in MKs derived from Rac1-/-, Cdc42-/- and Rac1/Cdc42-/- mice. (a-
c) Determination of the ploidy status from cultured MKs derived from wild-type, Rac1-/-, Cdc42-/- and 
Rac1/Cdc42-/- mice. (a) Representative dotplots. (b) Results from MKs derived from whole bone 
marrow. (c) Results from fetal liver-derived MKs (day 3 of culture). Results are expressed as mean 
ploidy (from 8 N)  SD from at least 4 samples per group. 
 
 
3.3.2.4 Reduced presence of demarcation membranes in bone marrow MKs 
from Cdc42-/- and Rac1/Cdc42-/- mice 
The results shown above revealed decreased proplatelet formation from cultured 
Cdc42-/- and Rac1/Cdc42-/- MKs. However, as mentioned in the Introduction (section 
1.3), recent studies indicate that the characteristic proplatelet structures found in in 
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vitro cultures do not exactly reflect the physiological situation of (pro)platelet 
formation. In vivo, membrane invaginations, called demarcation membranes (DMS), 
define newly formed proplatelet territories in the cytoplasm of mature MKs and 
proplatelets are shed into sinusoids of the marrow to allow shear-dependent platelet 
formation.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 42. Altered morphology of bone marrow MKs derived from Cdc42-/- and Rac1/Cdc42-/- 
mice. (a-d) TEM of MKs in bone marrow of adult (6 week-old) mice. (a,b) Normal ultrastructure in MKs 
derived from (a) wild-type and (b) Rac1-/- mice. (c,d) altered ultrastructure in MKs derived from (c) 
Cdc42-/- and (d) Rac1/Cdc42-/- mice. Note the absence of membrane invaginations and lack of the 
peripheral zone (PZ) in Rac1/Cdc42-/- MKs. Abbreviations: DMS, demarcation membrane system; PT, 
proplatelet territory. Bar sizes are depicted. 
PZ 
PZ 
PT 
PT 
DMS 
 
 
To visualize megakaryocyte maturation in the physiological environment, bone 
marrow sections from wild-type, Rac1-/-, Cdc42-/- and Rac1/Cdc42-/- mice were 
analyzed by TEM (Fig. 42/43). Mature wild-type, as well as Rac1-/- MKs displayed 
demarcation membranes and proplatelet territories in the center of the cytoplasm, 
whereas few invaginations were found in the periphery and around the nucleus (Fig. 
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42/43a,b). In Cdc42-/- MKs, membrane invaginations were still present but reduced 
as compared to MKs from wild-type mice, resulting in enlarged proplatelet territories 
and large areas without visible membrane invagination (Fig. 42/43c).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 43. Reduced membrane invagination in bone marrow MKs derived from Cdc42-/- and 
Rac1/Cdc42-/- mice. (a-d) Detailed transmission electron microscopy of MKs in bone marrow of adult 
(6 week-old) mice. (a,b) Presence of demarcation membranes and proplatelet territories in MKs 
derived from (a) wild-type and (b) Rac1-/- mice. (c) Partially reduced membrane invagination in Cdc42-/- 
MKs. (d) Abrogated membrane invagination and altered granule distribution/content in Rac1/Cdc42-/- 
MKs. Bar, 0.6 µm. 
 
By marked contrast, demarcation membranes were hardly present in MKs from 
Rac1/Cdc42-/- mice or concentrated in small areas (Fig. 42/43d). Furthermore, 
double-deficient MKs displayed reduced numbers of granules and an incomplete 
peripheral zone structure, resulting in reduced delineation of the MKs to circumjacent 
cells (Fig. 42d). This interesting observation is in line with the reduced visibility of 
Rac1/Cdc42-/- MKs in hematoxylin eosin-stained bone marrow sections (Fig 39b). 
Taken together, these results indicate new and redundant roles for Rac1 and Cdc42 
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in the regulation of MK maturation, including invagination of demarcation 
membranes, proplatelet territory formation and maintenance of cell integrity. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
4  Discussion 
4 DISCUSSION 
 
Platelet activation and aggregation at sites of vascular injury is essential to limit blood 
loss, but under pathological conditions it can lead to complete vessel occlusion 
resulting in myocardial infarction or stroke. Therefore, platelet signaling has become 
an important field of clinical research over the last decades and many widely used 
therapeutical drugs for prevention of cerebro- and cardiovascular diseases, such as 
aspirin and clopidogrel, act by inhibiting platelet function.  
Platelet activation induces a massive reorganization of the actin cytoskeleton which 
enables adhesion and spreading on ligands immobilized on the injured vessel wall. 
Small GTPases of the Rho family, namely RhoA, Rac1 and Cdc42 have been shown 
to contribute to these processes by inducing the formation of stress fibers, 
lamellipodia and filopodia, respectively. Furthermore, recents reports strongly 
indicate that the proteins may participate in a variety of additional pathways 
independent of their major proposed role as regulators of the actin cytoskeleton. 
A large number of studies addressing the role of Rho GTPases in various cell types, 
including platelets, have been performed, mainly by use of cell lines and 
overexpression systems. However, many of these studies yielded conflicting results 
which were most probably caused by unspecific side effects of the used methods 
and/or reagents. The recent generation of conditional knock-out mice for several 
GTPases has enabled the study of GTPase deficiency with a minimal risk of 
secondary effects.  
In the current thesis, the role of the Rho GTPases Rac1 and Cdc42 for platelet 
function and production was investigated using conditional single- and double-
deficient knock-out mice (Cre/loxP system). The results presented here reveal 
important and partially redundant roles for the GTPases and indicate so far unknown 
functions of Rac1 and Cdc42 in different platelet signaling pathways including not 
only regulation of actin cytoskeletal rearrangements, but also an involvement in 
platelet activatory and secretory events. Thus, Rho GTPases may serve as new 
potential targets for the development of agents in order to treat cerebro- and 
cardiovascular diseases. 
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4.1 Rac1 mediates phospholipase C-2 activation in platelets independently of 
tyrosine phosphorylation 
Binding of the major collagen platelet receptor GPVI to its ligand at sites of vascular 
injury is crucial for platelet activation, as well as subsequent aggregation and plug 
formation and involves activation of the phospholipase isoform PLC (see section 
1.1). The results presented here using gene targeting (Mx-Cre/loxP) reveal that the 
small GTPase Rac1 is required for ITAM-dependent activation of PLC2 in platelets. 
Deficiency in Rac1 resulted in defective GPVI-induced calcium mobilization and entry 
leading to severely defective platelet adhesion and thrombus formation on collagen in 
vitro and at the injured vessel wall in vivo (Fig. 16/17). In addition, it was shown that 
Rac1 is involved in platelet activation through CLEC-2 which employs a similar 
signaling pathway as GPVI involving Src family kinases, such as spleen tyrosine 
kinase (Syk) and PLC28;81 and thus represents an “ITAM-like” pathway. On the other 
hand, Rac1-/- platelets showed unaltered Ca2+ mobilization and cellular activation in 
response to GPCR stimulation, suggesting that the GTPase is not involved in PLC 
activation in platelets (Fig 13/14). This stands in contrast to results by Akbar et al. 
who reported a pronounced secretion defect in response to all tested agonists in 
Rac1-deficient mouse platelets and human platelets treated with a selective Rac1 
inhibitor44. However, in line with the results shown in this thesis, McCarty et al. also 
found unaltered secretion and aggregation of Rac1-/- platelets in response to GPCR-
coupled agonists33. It is difficult to explain the discrepancies in the results, but they 
may be due to different experimental conditions. 
Despite the severe defect in GPVI-induced cellular activation, no significant 
alterations in tyrosine phosphorylation patterns were detectable in the absence of 
Rac1 (Fig. 15). Importantly, also GPVI-induced PLC2 phosphorylation was 
indistinguishable between wild-type and Rac1-/- platelets. However, GPVI-induced IP3 
production and Ca2+ mobilization were severely impaired in the mutant platelets (Fig. 
14/15a). This clearly shows that Rac1 acts as a co-activator of PLC2 that regulates 
the enzyme independently of tyrosine phosphorylation events in murine platelets. 
Such a mechanism has recently been proposed by Piechulek et al. based on data 
obtained in heterologous cells and cell-free systems46. They showed that PLC2 
activation induced by constitutively active Rac1 was independent of phosphorylation 
of tyrosine residues known to be modified by PLC2-activating protein-tyrosine 
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kinases. The modality of interaction of Rac1 with PLC2 and the mechanisms 
involved are not clear at present. Piechulek et al. proposed a direct interaction of 
activated Rac1 with one of the pleckstrin homology (PH) domains of PLC2 as it was 
shown for PLC1 where a split PH domain is known to be responsible for protein-
protein interactions93;94. Interestingly, a recent study from Guidetti et al. showed that, 
in human platelets, integrin 21 signaling induced Rac1-mediated PLC2 activation 
without requiring tyrosine phosphorylation of the enzyme95. Thus, different 
mechanisms for PLC2 activation may exist in murine and human platelets, or, 
alternatively, the mechanism of Rac1-mediated PLC2 activation by integrin 21 
differs from that induced by GPVI. Clearly, further studies are required to resolve this 
issue. 
In this work, impaired aggregation of Rac1-/- platelets was found in response to low 
and intermediate concentrations of collagen and CRP, whereas largely normal 
responses were observed at high agonist concentrations (Fig. 11). However, these 
aggregometric studies had underestimated the severity of the defect in GPVI-
dependent activation as flow cytometric analysis revealed a dramatic impairment of 
cellular activation even at very high agonist concentrations (Fig. 13a-c). Moreover, 
dense granule secretion, as determined by measuring released ATP, was almost 
abolished in Rac1-/- platelets upon induction of GPVI signaling (Fig. 13d). It is known 
that in standard aggregometry robust platelet aggregation can be achieved even 
under conditions of very weak integrin αIIbβ3 activation82;96. In addition, released 
secondary mediators such as ADP and TXA2 accumulate in the aggregometer 
cuvette and to a great extent induce/amplify the observed aggregation response. 
Both of these factors probably contributed to the aggregation of Rac1-/- platelets in 
response to high collagen or CRP concentrations. This notion is supported by the 
finding that Rac1-/- platelets were unable to aggregate in response to high 
concentrations of collagen or CRP under conditions excluding the contribution of 
ADP and TXA2 (Fig. 12).  
Similar to McCarty et al., reduced adhesion of Rac1-/- platelets to collagen and 
virtually abrogated thrombus formation was observed in this study (Fig. 16/17). 
However, McCarty et al. proposed this aggregate instability to be based on altered 
cytoskeletal regulation leading to instable aggregate formation33. Although the defect 
in lamellipodia formation could also be confirmed in the current study (Fig. 10b) this 
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did most likely not account for the observed thrombus instability since co-infusion of 
ADP and U46619 to the flow system fully restored the ability of Rac1-/- platelets to 
form large stable three-dimensional thrombi (Fig. 16). Furthermore, as revealed by 
SEM, Rac1-/- and wild-type platelets displayed similar morphology when activated in 
suspension, which represents the physiological situation in the blood stream (Fig. 
10c). This surprising finding demonstrates that lamellipodia formation may not be 
required for thrombus stability, at least under the here described experimental 
conditions. Rather, the data suggest that the observed defect is based on insufficient 
GPVI-mediated platelet activation and release of secondarily acting agonists. In fact, 
the adhesion and thrombus formation defect observed in Rac1-/- mice is very similar 
to that previously seen in Plcg2-/- mice97. 
GPVI has been established as an attractive antithrombotic target70;86 also making its 
downstream signaling cascade interesting for inhibition. In addition, CLEC-2 was very 
recently identified by our group as an important platelet-activating receptor most 
probably required for recruitment and activation of further platelets in a growing 
thrombus98. Therefore, the pathway involving Rac1 downstream of GPVI and CLEC-
2 might be an attractive target for new anti-platelet agents to prevent thrombotic 
events. This was confirmed by the protection of Rac1-deficient mice from arterial 
thrombosis (Fig.17). Thus, inhibitors of Rac199 might be effective in the prophylaxis or 
treatment of ischemic cerebro- or cardiovascular diseases.  
 
4.2 A complex phenotype dominated by increased secretion in mice lacking  
Cdc42 in platelets 
In the present study, a knock-out approach (PF4-Cre/loxP) was used to investigate 
the effect of Cdc42 deficiency on platelet function in vitro and in vivo. It was found 
that megakaryocyte- and platelet-specific deletion of the Cdc42 gene resulted in mild 
thrombocytopenia, increased platelet size and, unexpectedly, increased secretion 
and a shortened platelet life span in mice. On the other hand, the herein presented 
results did not confirm the proposed major role of Cdc42 for filopodia formation in 
platelets32. 
The results of this study clearly show that Cdc42 is neither required for platelet 
filopodia formation and full spreading on fibrinogen upon activation with thrombin 
(Fig. 19a,b/20b), nor for morphological changes under non-stimulating conditions 
 82
4  Discussion 
(Fig. 19c) or upon stimulation with ADP (not shown). This indicates the involvement 
of proteins other than Cdc42 in filopodia formation on fibrinogen under conditions of 
G-protein coupled signaling. This finding is in accordance with results from Czuchra 
et al. who - also using a genetic approach - have demonstrated that Cdc42 is 
dispensable for filopodia formation, migration, polarization and mitosis in embryonic 
fibroblasts57. Recent data suggest the existence of Cdc42-independent mechanisms 
of filopodia formation, mainly involving the Rho GTPase Rif and LPR155;56. Thus, one 
of these proteins may act in filopodia formation in Cdc42-/- platelets. Interestingly, 
studies of platelet ultrastructure revealed no differences in filopodia morphology 
between Cdc42-/- and wild-type platelets (Fig. 20b,c), whereas filopodia induced by 
Rif and LPR1 were shown to have a longer and more hairy appearance than those 
induced by Cdc42. Clearly, further studies are required to investigate the signaling 
pathways that lead to agonist-induced filopodia formation in platelets.  
Notably, Cdc42-/- platelets displayed a clear defect in GPIb signaling-dependent 
filopodia formation induced by adhesion on vWF (Fig. 21a,b) which was most likely 
not caused by decreased GPIb expression levels since agglutination induced by 
botrocetin and human vWF was unaltered in the mutant cells (Figure 21c). This 
finding is intriguing since it establishes Cdc42 as a GPIb-specific downstream 
signaling molecule. A role of Cdc42 in platelet filopodia formation has been 
previously proposed downstream of the human platelet integrin 61 using 
secramine A as a Cdc42 specific inhibitor32. It was found that secramine A also 
prevented the GPIb-dependent response (Nieswandt and Gachet, personal 
communication) but non-specific effects of this compound were suggested by its 
ability to induce shape change in resting platelets. The signaling pathway 
downstream of GPIb leading to filopodia formation remains to be fully characterized. 
Under the assay condition used in this study, which prevents signal amplification by 
the IIb3 integrin, ADP or TXA2, the signaling response evoked by GPIb involves 
calcium mobilization from intracellular stores downstream of a Src kinase and 
PLC2100 (see also Fig. 2). These effectors are not restricted to GPIb signaling but 
also take part in GPVI and Fc receptor/ITAM-dependent activation, as demostrated in 
this thesis (see chapter 3.1). An increased rather than decreased response of Cdc42-
/- platelets to CRP and collagen observed here reinforces the notion of a GPIb-
restricted role of Cdc42 and indicates existence of a separate pathway unrelated to 
those induced by ITAM-coupled receptors. This hypothesis is consistent with reports 
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showing biochemical and functional interaction of Cdc42 with two known GPIb 
partners, filamin and 14-3-3101;102. 
Unexpectedly, Cdc42-/- platelets displayed increased secretion in response to agonist 
stimulation, whereas integrin IIb3 activation was slightly decreased (Figure 22/23). 
A significant increase in P-selectin expression despite unaltered protein content 
strongly indicates enhanced secretion of  granules in Cdc42-/- platelets (Fig. 
22/24a). In contrast, the observed strong increase of dense granule-dependent ATP 
release conincided with a significantly increased ADP/ATP content in the mutant 
platelets that may only partially be explained by their increased size since content 
and release of the dense granular mediator serotonin was not significantly altered 
(Fig. 23/24c,d). Thus, the increase in ADP/ATP content might contribute to the hyper-
reactivity observed in aggregometry where released mediators accumulate and to a 
great extent reinforce platelet activation and secretion. However, Cdc42 may also 
have a direct function in the degranulation machinery as increased P-selectin 
exposure was observed also in flow cytometric studies (Fig. 22), where highly diluted 
platelet samples are analyzed under conditions that minimize the influence of 
released mediators on the activation state of the cells82. 
The results of this study stand in contrast to a report by Pula et al., who found that 
platelets treated with the Cdc42 inhibitor secramine A show a selective aggregation 
and adhesion defect in response to collagen103. This discrepancy is difficult to explain 
at present but it might be related to limited specificity of the inhibitor. The observed 
increased secretion in Cdc42-/- platelets stands in clear contrast to observations 
made in other cell types showing decreased exocytosis upon inhibition of Cdc42, 
including endothelial cells and mast cells63;65;66. This indicates that Cdc42 might be 
able to fulfil multiple functions that may differ between cell types, however, 
methodological differences may as well account for the discrepant results. For the 
studies presented in this thesis, a direct genetic approach was used to delete Cdc42 
expression/function in vivo, whereas all other here mentioned studies used cell 
culture systems and transfection models. Notably, Czuchra et al. showed that 
expression of dominant-negative Cdc42 in Cdc42-null cells most likely resulted in the 
inhibition of other Rho GTPases, thereby significantly influencing the observed 
phenotype57. This finding would be in accordance with the observation by Hong-
Geller et al. who indeed observed an unexplained decrease in exocytosis when 
overexpressing wild-type Cdc42 in RBL mast cells65. 
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Cdc42-/- platelets formed larger aggregates on collagen under flow in vitro (Fig. 26). 
Although this effect was significant it was surprisingly moderate suggesting that the 
amount of released granule content may not be the only determinant of thrombus 
growth under these conditions. In line with this observation, the recent analysis of 
mice lacking functional CLEC-2 revealed that this receptor plays a fundamental role 
in the activation of platelets in a growing aggregate/thrombus under flow98 (see also 
section 3.1). Very similar to the results obtained by flow adhesion studies in vitro, 
thrombus formation in Cdc42-/- mice was found to be significantly accelerated in an 
arterial injury model in vivo (Fig. 29). Considering the increased secretion observed 
in Cdc42-/- platelets in vitro one might speculate that this effect was caused by the 
increased presence of platelet released thrombogenic factors at the site of injury. 
This notion would be in line with studies from other groups demonstrating the 
significance of degranulation-dependent release of platelet agonists, such as ADP 
and ATP, for thrombus formation under physiological conditions104;105. Furthermore, 
the here presented results clearly show that effective thrombus formation can still 
take place under conditions of decreased circulating platelets numbers106. In contrast 
to these observations, Cdc42-deficient mice displayed variable, but significantly 
prolonged bleeding times, clearly indicating impaired platelet plug formation (Fig. 28). 
Possibly, the impaired GPIb-dependent signaling observed in Cdc42-/- platelets (Fig. 
21a,b) contributed to this effect. Furthermore, decreased GPIb expression levels and 
decreased integrin IIb3 activation in Cdc42-/- platelets may also influence their 
function in this assay107.  
Cdc42-/- platelets displayed a markedly decreased life span (Fig. 27). It is 
hypothesized that this effect was at least in part caused by increased clearing of the 
platelets, which would suggest a non-functional or pre-activated state of the cells 
under physiological conditions in vivo. In line with this hypothesis, the constant 
removal of such pre-activated Cdc42-/- platelets might contribute to the 
thrombocytopenia in Cdc42-deficient animals. Furthermore, as shown by 
megakaryocyte studies, decreased proplatelet formation from Cdc42-/- MKs also 
contributed to the decreased platelet counts in Cdc42-/- animals. 
The results presented here indicate a new regulatory role for Cdc42 in platelet 
activatory/secretory events in vitro and in vivo. Importantly, the increased secretion of 
Cdc42-/- platelets was not restricted to a specific agonist but occurred in response to 
G protein-, as well as ITAM-coupled agonists, indicating a general function of the 
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Cdc42 protein in platelet granule content organization and secretion. In line with this, 
the increased ADP/ATP content suggests that Cdc42 may be required for proper 
granule formation/packing during platelet production. Moreover, our results indicate 
that Cdc42 deficiency directly leads to enhanced secretion of  granules in platelets.  
Currently, the exact role of the regulation of actin cytoskeleton in exocytotic events in 
platelets is controversial. Several studies using actin-disrupting agents supported a 
model in which the cytoskeleton in resting platelets may act as a barrier for granule 
release and that platelet activation leads to (partial) disrupture of actin filaments, 
thereby enabling degranulation108. However, this model is questioned because of the 
risk of artefacts caused by actin-disrupting agents. To test a possible effect of Cdc42 
deficiency on agonist-induced cytoskeletal rearrangements, the Cdc42 downstream 
effector cofilin was examined, a protein known to be involved in increasing actin 
turnover in its active dephosphorylated form90. Unexpectedly, and in contrast to the 
currently proposed function of Cdc42109, not a decrease, but a strong (approximately 
2-fold) increase in the (inactive) phosphorylated cofilin form was found in resting 
Cdc42-/- platelets as compared to controls (Fig. 30a,b). This finding is in accordance 
with a recent study showing increased cofilin phosphorylation in cortical neurons 
upon genetic Cdc42 deletion91. Thrombin- and CRP-induced dephosphorylation of 
cofilin occurred to a similar extent and with similar kinetics in wild-type and Cdc42-/- 
platelets, although higher levels of the inactive, phosphorylated form of the protein 
were consistently detected in the mutant cells under all experimental conditions (Fig. 
30c). Furthermore, similar levels of F-actin in resting and thrombin-activated Cdc42-/- 
and wild-type platelets were observed (Fig. 37b), indicating that a reorganization 
rather than a disassembly of actin might be responsible for the cytoskeletal effects 
evoked by Cdc42 deficiency. Further studies are ongoing to determine the role of 
Cdc42 in actin turnover regulation during platelet degranulation. 
In addition to actin remodeling, Cdc42 could also participate directly or indirectly in 
the exocytotic processes in platelets. Recently, it became evident that platelets 
possess a secretory machinery similar to that of other cell types110;111;112. Thus, 
Cdc42 may be involved in signaling events during platelet exocytosis which may be 
of importance for rapid but controlled platelet degranulation upon activation.  
Taken together, the results from this study have revealed multiple and novel roles for 
Cdc42 during platelet activation and granule organization/exocytosis, whereas its 
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proposed essential role for filopodia formation in the cells could not be confirmed, 
except under conditions of selective GPIb dependent activation. These findings point 
to Cdc42 and/or its downstream effector molecules as potential targets for the 
development of novel drugs for the regulation of intravascular platelet activation. 
 
4.3 Rac1 and Cdc42 play redundant roles in megakaryocyte maturation and 
platelet formation 
The results presented in the first two parts of this thesis focused on the effect of 
either Rac1 or Cdc42 deficiency on platelet function in vitro and in vivo. In the 
following, it was of interest to investigate the effect of deletion of both GTPases for 
platelet function. Furthermore, the impact of GTPase deficiency on platelet 
production from MKs was assessed. 
As already mentioned, very little is known about the role of Rho GTPases and the 
actin cytoskeleton in MK maturation and platelet formation. Since Rac1 and Cdc42 
have been shown to both induce activation of p21-activated kinase (PAK) isoforms 
and thus might share similar downstream signaling pathways92;113, it was of interest 
to study a putative redundant role of the GTPases in platelet function and production. 
To study this, double-deficient mice were generated using the PF4-Cre/loxP system 
for MK studies and the Mx-Cre/loxP system for platelet studies. In parallel, the single-
deficient animals generated by the PF4-Cre/loxP approach were also analyzed.  
MK numbers were normal in spleen and bone marrow of Rac1-/- mice (Fig 39). 
Furthermore, Rac1-/- bone marrow MKs displayed no changes in ultrastructure and in 
vitro proplatelet formation from the mutant MKs was unaltered as compared to wild-
type MKs (Fig. 40) resulting in normal platelet counts with unaltered life span in Rac1-
/- mice (Fig. 9c). These results confirm our and other studies33;44 that Rac1 is 
dispensable for MK maturation and platelet production. 
So far, the role of Cdc42 during MK maturation and platelet production has not been 
directly addressed, although the GTPase was recently speculated to positively 
regulate proplatelet formation during late MK maturation26. Indeed, in this study, a 
significant reduction in proplatelet formation from Cdc42-/- MKs in vitro was observed 
(Fig. 40). In situ analysis of Cdc42-/- MKs in bone marrow revealed partially reduced 
invagination of demarcation membranes and enlargement of proplatelet territories 
(Fig. 42/43). As a compensatory mechanism for decreased platelet production from 
 87
4  Discussion 
Cdc42-/- MKs and the shortened life span of Cdc42-/- platelets (Fig 27), MK numbers 
were highly increased in spleen and bone marrow of the mutant mice (Fig. 39). Thus, 
the results presented in this thesis clearly demonstrate a role for Cdc42 in late MK 
maturation, thereby significantly affecting platelet production and function as 
demonstrated by the study of Cdc42-/- platelets.  
Interestingly, the phenotype observed in Cdc42-/- MKs was in many respects similar 
to MKs lacking the GPIb subunit of the GPIb/V/IX complex114. Like Cdc42-/- MKs, 
GpIb-/- MKs displayed normal ploidy and maturation, but less development of 
demarcation membranes and reduced proplatelet formation. Although GPIb 
deficiency had a more severe impact on platelet production and function one might 
speculate that Cdc42 may act as a downstream effector of GPIb during 
megakaryocyte maturation and (pro)platelet formation. This hypothesis is supported 
by our observation that Cdc42 is involved in GPIb signaling also in platelets (Fig. 21). 
Further studies are ongoing to resolve the signaling processes involved in Cdc42 
activation and downstream signaling during MK maturation. 
This study showed that already Cdc42 deficiency alone affected MK maturation and 
platelet production, although the resulting phenotype was relatively mild. On the other 
hand, Rac1 was dispensable for platelet production. In contrast, combined deletion of 
both GTPases resulted in normal MK ploidy but strongly reduced proplatelet 
formation in vitro (Fig. 41/40). Bone marrow MKs from Rac1/Cdc42-/- mice exhibited 
dramatically reduced demarcation membrane invagination and proplatelet territory 
formation, indicating an important role of the GTPases in morphological 
rearrangements necessary for these processes (Fig. 42/43). Furthermore, Rac1 and 
Cdc42 seemed to be required for efficient granule synthesis and for the structural 
integrity of mature MKs as revealed by the partial absence of peripheral zones and 
loss of demarcation of Rac1/Cdc42-/- MKs to surrounding cells in situ. A similar MK 
phenotype has been described recently using mice with MK- and platelet-restricted 
myosin IIA deficiency27 confirming an important role of cytoskeletal rearrangements 
for proper MK maturation. Preliminary studies from our group on actin/tubulin 
dynamics in Rac1/Cdc42-/- furthermore indicate increased presence of tubulin coils in 
the periphery and in proplatelets of double-mutant MKs, suggesting a role of the 
GTPases in microtubule organization during proplatelet formation. This hypothesis is 
in line with results from studies in fibroblasts and neurons28;115. Abnormal tubulin 
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organisation was also observed by Strassel et al. in MKs lacking GPIb, further 
emphasizing a potential role of GTPase signaling downstream of GPIb in MKs114. 
As a result from defective (pro)platelet formation, Rac1/Cdc42-/- animals displayed 
marked thrombocytopenia which was probably predominantly caused by decreased 
platelet production from Rac1/Cdc42-/- MKs and by the constant clearing of non-
functional platelets from the vascular system. Circulating Rac1/Cdc42-/- platelets 
showed severely altered morphology and displayed multiple activation and functional 
defects resulting in defective hemostasis and in vivo thrombus formation (Fig. 32-38). 
Taken together, the results presented here demonstrate that, whereas lack of either 
Rac1 or Cdc42 alone resulted in no or relatively mild effects on megakaryocyte 
maturation, platelet production and function, double deficiency of Rac1 and Cdc42 
abrogated the maturation of MKs and thus the production of functional platelets. This 
demonstrates for the first time a functional redundany of Rac1 and Cdc42 in the 
positive regulation of these processes. Together with the recently described role of 
RhoA as a negative regulator, these findings emphasize that differential signaling 
from Rho GTPases is significantly involved in MK maturation and platelet formation in 
mice. 
 
4.4 Concluding remarks and outlook 
The work presented here provides new insights into the role of the Rho GTPases 
Rac1 and Cdc42 for platelet function and their production from megakaryocytes 
using genetically modified mice.  
In humans, mutations and/or deficiencies of Rho GTPases have not been described, 
most probably because such alterations would be associated with early lethality 
during embryogenesis. Importantly, this study points out that the mouse system 
bears several advantages for analysis of GTPase function. By the use of conditional 
knock-out mice an otherwise lethal phenotype is circumvented and gene deletion can 
be restricted to the desired cell type. Furthermore, side effects often occurring when 
using cellular overexpression systems or inhibitors for study of GTPase function are 
avoided by this method.  
Further studies are planned in our laboratory to investigate the function of Rho 
GTPases not only in platelets and megakaryocytes, but also in cells of the immune 
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system. This includes the study of Rac1-deficient macrophages, as well as deeper 
analysis of the exact function of Cdc42 in megakaryocytes and platelets, focusing on 
its role in GPIb signaling. Together with the analysis of recently generated 
megakaryocyte- and platelet-specific RhoA knock-out mice, these studies will shed 
new light on the impact of GTPase signaling for cellular function. 
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6 APPENDIX 
 
Abbreviations 
 
aa     amino acid 
AC            adenylate cyclase 
ADP             adenosine diphosphate 
APS      ammonium peroxodisulphat  
ARP      actin-related protein 
ATP      adenosine trisphosphate 
BFU         burst-forming units 
BSA      bovine serum albumin  
°C     degree Celsius 
CFSE                   carboxyfluorescein succinimidyl ester 
CFU         colony-forming units 
CLEC-2    C-type lectin-like receptor 2 
[Ca2+]i        intracellular calcium concentration 
cm²     square centimetre 
CRP         collagen-related peptide 
CVX        convulxin 
DAG     diacylglycerol 
ddH2O     double-distilled water 
DIC     differential interference contrast 
DMEM                                Dulbecco/Vogt Modified Eagle's Minimal Essential 
                                           Medium 
DMS     demarcation membrane system 
E              embryonic day 
ECL     enhanced Chemiluminescence 
ECM     extracellular matrix 
EDTA     ethylenediaminetetraacetic acid 
ELISA        enzyme-linked immuno absorbance assay 
et al.     et alteri 
F-actin    filamentous actin 
f.c.     final concentration 
Fc     Fragment crystallisable 
FcR     Fc receptor 
FCS     fetal calf (bovine) serum 
Fg     fibrinogen 
Fig.     figure 
FITC       fluorescein isothiocyanate 
FSC        foreward scatter 
g     gramme 
GAP        GTPase-activating protein 
GATA      globin transcription factor 
GAP        GTPase-activating protein 
GDP        guanosine diphosphate 
GEF         guanine nucleotide exchange factor 
GM-SCF          granulocyte macrophage colony-stimulating factor 
GP     glycoprotein 
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GPCR     G protein-coupled receptor 
GTP         guanosine trisphosphate 
h     hour(s) 
HCl     hydrogen chloride 
HPLC              high- performance liquid chromatography  
HRP     horseradish peroxidase 
HSC        hematopoietic stem cell 
H2O     water 
IFI              integrated fluorescence intensity 
Ig     immunoglobulin 
IL     interleukin 
IMDM      Iscove's Modified Dulbecco's Medium 
IP     immunoprecipitation 
IP3     inositol 1,4,5-trisphosphate 
IRSp53     insulin-receptor substrate p53 
ITAM     immunoreceptor tyrosine-based activation motif 
kb     kilo base pair 
kDa     kilo Dalton 
l     litre 
LAT     linker for activation of T-cells 
LIMK       LIM kinase 
LPR1               lipid-phosphatase-related protein-1 
M     molar 
MFI         mean fluorescence intensity 
min     minute(s) 
MK     megakaryocyte 
ml     millilitre 
MLC         myosin light chain 
mm     millimetre 
µ     micro 
NaCl     sodium chloride 
NaOH     sodium hydroxide 
NF-E2     nuclear factor (erythroid-derived 2) 
OD     optical density 
o/n     overnight 
PAA     polyacrylamide 
PAK     Ser/Thr p21-activated kinase 
PBS     phosphate buffered saline 
PCR     polymerase chain reaction 
PE           phycoerythrin 
PF4     platelet factor 4 
PH     pleckstrin homology 
PI     propidium iodide 
PIP2        phosphatidyinositol-4,5-bisphosphate 
PI-3-K              phosphoinositide-3-kinase 
PKC     proteinkinase C 
PL (C)     phospholipase (C) 
PMA       phorbol 12 myristate 13 acetate 
PPF           proplatelet formation 
pI-pC           polyinosinic-polycytidylic acid 
PCR     polymerase chain reaction 
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prp            platelet-rich plasma 
PT             proplatelet territory 
PVDF       polyvinylidene difluoride 
PZ             peripheral zone 
RC            rhodocytin 
Rif               Rho in filopodia 
rpm     rounds per minute 
RT     room temperature 
s             second(s) 
SD             standard deviation 
SDF          stromal cell-derived factor 
SDS     sodium dodecyl sulfate  
SDS-PAGE                        sodium dodecyl sulfate polyacrylamide gel electrophoresis 
SEM                scanning electron microscopy 
SLP-76    Src-homology 2 domain-containing leukocyte- 
   specific phospho-protein of 76 kDa 
SOCE     store-operated Ca2+ entry 
SSC           sideward scatter 
Syk     spleen tyrosine kinase 
TAE     TRIS acetate EDTA buffer 
TE     TRIS EDTA buffer 
TEM          transmission electron microscopy 
TF     tissue factor 
TPO                thrombopoietin 
TRIS     trishydroxymethylaminomethane 
TxA2         thromboxane A2 
U     units 
vWF     von Willebrand factor 
WASP      Wiscott-Aldrich syndrome protein 
WAVE      WASP family verprolin-honologous protein 
wt     wild-type 
x g    acceleration of gravity (9.81 m/ s²) 
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